Bionik Laboratories (BNKL) S-1 23 Oct 15 IPO registration Financial data

Document And Entity Information

Document And Entity Information	6 Months Ended
	Jun. 30, 2015
Document Information [Line Items]
Entity Registrant Name	Bionik Laboratories Corp.
Entity Central Index Key	1,508,381
Entity Filer Category	Smaller Reporting Company
Document Type	S1
Amendment Flag	false
Document Period End Date	Jun. 30, 2015

Condensed Consolidated Interim

Condensed Consolidated Interim Balance Sheets - USD ($)	Jun. 30, 2015	Dec. 31, 2014	Mar. 31, 2014
Current
Cash and cash equivalents	$ 9,078,216	$ 209,933	$ 3,482
Prepaid expenses and other receivables (Note 3)	164,353	81,130	505,787
Due from related parties (Note 7)	42,151	44,986	0
Loan receivable (Note 4)	150,000	0
Total Current Assets	9,434,720	336,049	509,269
Equipment (Note 5)	114,544	77,922	6,752
Total Assets	9,549,264	413,971	516,021
Current
Accounts payable (Note 7)	197,082	308,947	120,751
Accrued liabilities	33,270	155,463	128,739
Convertible secured promissory note (Note 5)		0	119,112
Loans payable (Note 6)		0	772,146
Due to related parties (Note 7)		0	149,899
Total Liabilities	230,352	464,410	1,290,647
Shareholders' Equity (Deficiency)
Special Voting Preferred Stock, par value $0.001; Authorized - 1; Issued and outstanding - 1 (December 31, 2014 - Nil)	0	0
Common Stock, Value, Issued	72,408	49,737	1,658,585
Additional paid in capital	17,924,377	4,936,456	114,284
Deficit	(8,720,022)	(5,053,982)	(2,589,235)
Accumulated other comprehensive income	42,149	17,350	41,740
Total Shareholders' Equity (Deficiency)	9,318,912	(50,439)	(774,626)
Total Liabilities and Shareholders' Equity (Deficiency)	$ 9,549,264	$ 413,971	$ 516,021

Condensed Consolidated Interim3

Condensed Consolidated Interim Balance Sheets [Parenthetical] - $ / shares	Jun. 30, 2015	Dec. 31, 2014	Mar. 31, 2014
Preferred Stock, Par Value (in dollars per share)	$ 0.001	$ 0.001
Preferred Stock, Shares Authorized	1	1
Preferred Stock, Shares Issued	1	0
Preferred Stock, Shares Outstanding	1	0
Common Stock, Par Value (in dollars per share)	$ 0.001	$ 0	$ 0
Common Stock, Shares Authorized	150,000,000	200,000,000
Common Stock, Shares, Issued	22,408,313	0	11,641,667
Common Stock, Shares, Outstanding	22,408,313	0	11,641,667
Common Stock, Other Shares, Outstanding	50,000,000	49,737,096

Condensed Consolidated Interim4

Condensed Consolidated Interim Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended		6 Months Ended		9 Months Ended		12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014	Dec. 31, 2013	Mar. 31, 2014	Mar. 31, 2013
Expenses
Research and development	$ 609,823	$ 277,359	$ 1,045,493	$ 549,920	$ 1,178,837	$ 747,502	$ 937,426	$ 637,661
Professional and consulting fees	185,572	151,916	446,922	314,937	601,491	407,941	574,875	250,943
General and administrative	324,200	183,660	491,948	258,322	549,947	205,248	302,353	345,293
Imputed interest expense (Note 6)	0	0	0	30,711	27,677	55,647	101,985	7,282
Interest expense	9,963	5,094	10,363	22,269	6,212	10,868	28,629	0
Depreciation (Note 5)	17,002	11,492	27,414	22,691	34,036	1,349	1,772	2,330
Other income	(25,208)	(21,696)	(25,295)	(502,037)	(46,026)	0	(495,271)	(306,450)
Share-based compensation expense (Notes 8(v) and 9)	1,297,558	19,748	1,669,195	90,286	112,573	0	0	0
Operating Income (Loss)	(2,418,910)	(627,573)	(3,666,040)	(787,099)	(2,464,747)	(1,428,555)	(1,451,769)	(937,059)
Net loss for the period	(2,418,910)	(627,573)	(3,666,040)	(787,099)	(2,464,747)	(1,428,555)	(1,451,769)	(937,059)
Foreign exchange translation adjustment for the period	0	(3,116)	24,799	(3,098)	(24,390)	(553)	18,284	23,013
Net loss and comprehensive loss for the period	$ (2,418,910)	$ (630,689)	$ (3,641,241)	$ (790,197)	$ (2,489,137)	$ (1,429,108)	$ (1,433,485)	$ (914,046)
Loss per share - basic and diluted (in dollars per share)	$ (0.04)	$ (0.01)	$ (0.06)	$ (0.02)	$ (0.16)	$ (0.12)	$ (0.12)	$ (0.09)
Weighted average number of shares outstanding - basic and diluted (in shares)	68,765,736	46,022,905	57,773,973	41,390,813	15,358,291	11,602,879	11,612,900	10,375,937

Condensed Consolidated Interim5

Condensed Consolidated Interim Statements of Changes in Shareholders' Equity (Deficiency) - USD ($)		Total	Preferred Stock [Member]	Common Stock [Member]		Additional Paid-in Capital [Member]	Deficit [Member]	Accumulated Other Comprehensive Income [Member]
Balance at Mar. 31, 2012		$ (183,721)		$ 5	[1]	$ 16,238	$ (200,407)	$ 443
Balance (in shares) at Mar. 31, 2012	[1]			9,000,000
Issuance of common shares for cash (Note 8(i))		1,486,980		$ 1,486,980		0	0	0
Issuance of common shares for cash (Note 8(i)) (in shares)				2,525,000
Issuance of common shares for services		117,192		$ 117,192	[2]	0	0	0
Issuance of common shares for services (in shares)	[2]			200,000
Share issue costs		(34,583)		$ (34,583)		0	0	0
Cancellation of common shares issued to founders		0		$ 0		0	0	0
Cancellation of common shares issued to founders (in shares)				(250,000)
Net loss for the period		(937,059)		$ 0		0	(937,059)	0
Foreign currency translation		23,013		0		0	0	23,013
Balance at Mar. 31, 2013		471,822		$ 1,569,594		16,238	(1,137,466)	23,456
Balance (in shares) at Mar. 31, 2013				11,475,000
Net loss for the period		(1,428,555)
Foreign currency translation		(553)
Balance at Dec. 31, 2013		(710,982)	$ 0	$ 36,622		1,736,247	(2,506,754)	22,903
Balance (in shares) at Dec. 31, 2013			1	36,621,885
Balance at Mar. 31, 2013		471,822		$ 1,569,594		16,238	(1,137,466)	23,456
Balance (in shares) at Mar. 31, 2013				11,475,000
Issuance of common shares for cash (Note 8(i))		96,320		$ 96,320		0	0	0
Issuance of common shares for cash (Note 8(i)) (in shares)				166,667
Share issue costs		(7,329)		$ (7,329)		0	0	0
Relative fair value of options issued and contributed capital from shareholders		98,046		0		98,046	0	0
Net loss for the period		(1,451,769)		0		0	(1,451,769)	0
Foreign currency translation		18,284		0		0	0	18,284
Balance at Mar. 31, 2014		(774,626)		$ 1,658,585		114,284	(2,589,235)	41,740
Balance (in shares) at Mar. 31, 2014				11,641,667
Balance at Dec. 31, 2013		(710,982)	$ 0	$ 36,622		1,736,247	(2,506,754)	22,903
Balance (in shares) at Dec. 31, 2013			1	36,621,885
Balance at Dec. 31, 2014		(50,439)	$ 0	$ 4,837,844		4,936,456	(5,053,982)	17,350
Balance (in shares) at Dec. 31, 2014			1	49,737,096
Balance at Mar. 31, 2014		(774,626)		$ 1,658,585		114,284	(2,589,235)	41,740
Balance (in shares) at Mar. 31, 2014				11,641,667
Issuance of common shares for cash (Note 8(i))		2,616,062		$ 2,616,062		0	0	0
Issuance of common shares for cash (Note 8(i)) (in shares)				3,430,756
Share issue costs		(11,609)		$ (11,609)		0	0	0
Shares issues on conversion of loans (Notes 8(ii) and (iii))		239,746		$ 239,746		0	0	0
Shares issues on conversion of loans (Notes 8(ii) and (iii)) (in shares)				321,748
Beneficial conversion feature (Note 6)		27,677		$ 0		27,677	0	0
Shares issued on exercise of stock options (Note 8(iv))		228,875		$ 335,060	[3]	(106,185)	0	0
Shares issued on exercise of stock options (Note 8(iv)) (in shares)	[3]			416,667
Share compensation expense		112,573		$ 0		112,573	0	0
Net loss for the period		(2,464,747)		0		0	(2,464,747)	0
Foreign currency translation		(24,390)		0		0	0	(24,390)
Balance at Dec. 31, 2014		(50,439)	$ 0	$ 4,837,844		4,936,456	(5,053,982)	17,350
Balance (in shares) at Dec. 31, 2014			1	49,737,096
Effect of the Reverse Acquisition (Note 8(vii))		0	$ 0	$ 6,000		(6,000)	0	0
Effect of the Reverse Acquisition (Note 8(vii)) (in shares)			0	6,000,063
Shares issued on private placement		13,126,600	$ 0	$ 16,408		13,110,192	0	0
Shares issued on private placement (in shares)			0	16,408,250
Share issue costs		(1,785,203)	$ 0	$ 0		(1,785,203)	0	0
Share compensation expense (Notes 8(v) and 9)		1,669,195	$ 0	$ 263		1,668,932	0	0
Share compensation expense (Notes 8(v) and 9) (in shares)			0	262,904
Net loss for the period		(3,666,040)	$ 0	$ 0		0	(3,666,040)	0
Foreign currency translation		24,799	0	0		0	0	24,799
Balance at Jun. 30, 2015		$ 9,318,912	$ 0	$ 72,408		$ 17,924,377	$ (8,720,022)	$ 42,149
Balance (in shares) at Jun. 30, 2015			1	72,408,313
[1]	The opening balance consists of 7,750,000 common shares issued to its two founders for a consideration of $2, 1,000,000 commons shares issued to two directors and 250,000 common shares to a consultant for a total of 1,250,000 common shares for consideration of $3.
[2]	In May, 2012, 200,000 common shares valued at $117,192 were issued for settlement of accounts payable relating to services performed in the prior year, which is included in general and administrative expenses for the year ended March 31, 2013.
[3]	In June 2014, the Company issued 416,667 common shares for the exercise of stock options. The Company received cash of $228,875 ($250,000 CAD). The value of the options, $106,185, was transferred from contributed surplus to share capital on exercise.

Condensed Consolidated Interim6

Condensed Consolidated Interim Statements of Cash Flows - USD ($)	6 Months Ended		9 Months Ended		12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014	Dec. 31, 2013	Mar. 31, 2014	Mar. 31, 2013
Operating activities
Net loss for the period	$ (3,666,040)	$ (787,099)	$ (2,464,747)	$ (1,428,555)	$ (1,451,769)	$ (937,059)
Adjustment for items not affecting cash
Depreciation of equipment	27,414	22,691	34,036	1,349	1,772	2,330
Interest			0	0	19,223	0
Imputed interest	0	30,711	27,677	55,647	101,985	7,282
Share compensation expense	1,669,195	90,286	112,573	0	0	117,192
Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities	(1,969,431)	(643,411)	(2,290,461)	(1,371,559)	(1,328,789)	(810,255)
Changes in non-cash working capital items
Prepaid expenses and other receivables	(83,223)	(762,806)	420,709	393,900	(182,783)	(281,604)
Due from related parties	2,835	(27,696)
Accounts payable	(111,865)	(37,934)	195,427	116,122	41,261	25,195
Accrued liabilities	(122,193)	(176,510)	34,847	70,407	124,221	(11,238)
Net cash used in operating activities	(2,283,877)	(1,648,357)	(1,639,478)	(791,130)	(1,346,090)	(1,077,901)
Investing activities
Acquisition of equipment	(64,036)	(96,309)	(109,316)	(4,557)	0	(8,695)
Provision of a loan receivable	(150,000)	0
Net cash used in investing activities	(214,036)	(96,309)	(109,316)	(4,557)	0	(8,695)
Financing activities
Proceeds from issuance of shares, net of issue costs	11,341,397	2,656,097	2,604,453	88,991	147,837	1,393,551
(Repayment of) proceeds from loans payable			(733,293)	482,050	810,553	0
Proceeds from exercise of stock options	0	228,875	228,875	0	0	0
Repayment of loans from related parties	0	(199,737)	(111,357)	84,107	184,594	(117,946)
Net cash provided by financing activities	11,341,397	2,685,235	1,988,678	655,148	1,142,984	1,275,605
Effects of foreign currency exchange rate changes	24,799	(3,323)	(33,433)	23,706	(26,652)	29,288
Net increase in cash and cash equivalents for the period	8,868,283	937,246	206,451	(116,833)	(229,758)	218,297
Cash and cash equivalents, beginning of period	209,933	116,407	3,482	233,240	233,240	14,943
Cash and cash equivalents, end of period	9,078,216	1,056,803	209,933	116,407	3,482	233,240
Supplemental information:
Issuance of shares on conversion of loans	$ 500,000	$ 239,746	239,746	0	0	0
Interest paid			$ 0	$ 0	$ 9,406	$ 0

NATURE OF OPERATIONS

NATURE OF OPERATIONS	6 Months Ended	9 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Operations [Text Block]	1. NATURE OF OPERATIONS The Company and its Operations Bionik Laboratories Corp. (formerly Drywave Technologies Inc., the “Company” or “Bionik”) was incorporated on January 8, 2010 in the State of Colorado as Strategic Dental Management Corp. On July 16, 2013, the Company changed its name to Drywave Technologies Inc. (“Drywave”) and its state of incorporation from Colorado to Delaware. Effective February 13, 2015, the Company changed its name to Bionik Laboratories Corp. and reduced the authorized number of shares of common stock from 200,000,000 150,000,000 1-for-0.831105 The Company is a bioengineering research and development company targeting diseases and injuries that impact human mobility. The Company is working towards its first product, which will be the “ARKE”, a robotic pair of exoskeleton legs to be used for rehabilitation purposes and potentially for day-to-day use as a replacement for a wheelchair. These unaudited condensed consolidated interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("US GAAP"), which contemplates continuation of the Company as a going concern, which assumes the realization of assets and satisfaction of liabilities and commitments in the normal course of business. On February 26, 2015, the Company finalized a Share Exchange Agreement whereby Bionik Canada issued 50,000,000 3.14 100 As a result of the shareholders of Bionik Canada having a controlling interest in the Company subsequent to the Merger, for accounting purposes the Merger does not constitute a business combination. The transaction has been accounted for as a recapitalization of the Company with Bionik Canada being the accounting acquirer even though the legal acquirer is Bionik, accordingly, the historic financial statements of Bionik Canada are presented as the comparative balances for the period prior to the Merger. References to the Company refer to the Company and its wholly-owned subsidiaries, Bionik Acquisition Inc. and Bionik Canada. References to Drywave relate to the Company prior to the Merger. The Company has not yet realized any revenues from its planned operations. As at June 30, 2015, the Company had a working capital surplus of $ 9,204,368 9,318,912 3,641,241 790,197 The Company’s principal offices are located at 483 Bay Street, N105, Toronto, Ontario, M5G 2C9.	1. NATURE OF OPERATIONS The Company and its Operations Bionik Laboratories Inc. (the “Company” or “Bionik”) is a Canadian private company incorporated under the Canada Business Corporation Act on March 24, 2011 and domiciled in Ontario, Canada. The Company’s registered head office is located at 483 Bay Street, N105, Toronto, Ontario, M5G 2C9. The Company is a bioengineering research and development company targeting diseases and injuries that impact human mobility. The Company is working towards its first market ready product, which will be the “ARKE”, a robotic pair of exoskeleton legs to be used for rehabilitation purposes and potentially for day-to-day use as a replacement for a wheelchair. These financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("US GAAP"), which contemplates continuation of the Company as a going concern, which assumes the realization of assets and satisfaction of liabilities and commitments in the normal course of business. The Company has not yet realized any revenues from its planned operations. As December 31, 2014 the Company has a working capital deficit of $128,361 (March 31, 2014 - $781,378) and shareholders’ deficit of $ 50,439 774,626 2,489,137 1,429,108 1,433,485 914,046

SIGNIFICANT ACCOUNTING POLICIES

SIGNIFICANT ACCOUNTING POLICIES	6 Months Ended	9 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	2. SIGNIFICANT ACCOUNTING POLICIES Unaudited Condensed Consolidated Interim Financial Statements These unaudited condensed consolidated interim financial statements have been prepared on the same basis as the annual audited financial statements and should be read in conjunction with those annual audited financial statements filed on Form 10-K for the year ended December 31, 2014. In the opinion of management, these unaudited condensed consolidated interim financial statements reflect adjustments, necessary to present fairly the Company's financial position, results of operations and cash flows for the periods shown. The results of operations for such periods are not necessarily indicative of the results expected for a full year or for any future period. Recently Issued Accounting Pronouncements On May 28, 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers (Topic 606)”. The standard outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance. The accounting standard is effective for annual reporting periods (including interim reporting periods within those periods) beginning after December 15, 2017. Early adoption is not permitted. The impact on the condensed interim financial statements of adopting ASU 2014-09 will be assessed by management. On August 27, 2014, the FASB issued a new financial accounting standard on going concern, ASU No. 2014-15, “Presentation of Financial Statements – Going Concern (Sub-Topic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern.” The standard provides guidance about management’s responsibility to evaluate whether there is a substantial doubt about the organization’s ability to continue as a going concern. The amendments in this Update apply to all companies. They become effective in the annual period ending after December 15, 2016, with early application permitted. The impact on the condensed interim financial statements of adopting ASU 2014-15 will be assessed by management. Management does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the accompanying condensed consolidated interim financial statements. Foreign Currency Translation On April 1, 2015, Bionik Canada and Bionik Acquisition Inc. changed its functional currency from the Canadian Dollar to the U.S. Dollar. This reflects the fact that the majority of the Company’s business is influenced by an economic environment denominated in U.S. currency as well the Company anticipates revenues to be earned in U.S. dollars. The change in accounting treatment is applied prospectively. The functional currency is separately determined for the Company and each of its subsidiaries, and is used to measure the financial position and operating results. The functional currency of the Company and its wholly-owned subsidiaries is the U.S. dollar. Transactions denominated in a currency other than the functional currency are recorded on initial recognition at the exchange rate at the date of the transaction. After initial recognition, monetary assets and liabilities denominated in foreign currency are translated at the end of each reporting period into the functional currency at the exchange rate at that date. Exchange differences are recognized in profit or loss. Non-monetary assets and liabilities measured at cost are translated at the exchange rate at the date of the transaction.	2. SIGNIFICANT ACCOUNTING POLICIES The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates, and changes in these estimates are recorded when known. Significant estimates made by management include: investment tax credit receivable (see note 3) and the valuation allowance for deferred tax assets. The Company’s functional currency is the Canadian dollar and its reporting currency is the US dollar. The financial statements have been translated into US dollars in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 830. All assets and liabilities with Canadian dollars as functional currency are translated at the exchange rate on the balance sheet date, shareholders' equity and share issuances are translated at the historical rates and the statements of operations and cash flows are translated at the average exchange rate for the year. The resulting translation adjustments are reported under comprehensive income as a separate component of shareholders’ equity (deficiency). Equipment is recorded at cost. Depreciation is computed using the declining balance method, over the estimated useful lives of these assets. The costs of improvements that extend the life of equipment are capitalized. All ordinary repair and maintenance costs are expensed as incurred. Computers and electronics 50 Furniture and fixtures 20 Tools and parts 20 The Company has yet to recognize any revenue. The Company intends to record revenue when it is realized, or realizable and earned. The Company will consider revenue to be realized, or realizable and earned, when the following revenue recognition requirements are met: persuasive evidence of an arrangement exists; the products or services have been accepted by the customer via delivery or acceptance; the sales price is fixed or determinable; and collectability is reasonably assured. The Company receives certain grant and input tax credit recoveries from the Canadian government in compensation for eligible expenditures. These are presented as other income in the statements of operations and comprehensive loss as they generally relate to a number of the Company’s operating expenses, such as salaries and benefits, research and development and professional and consulting fees. The recoveries are recognized in the corresponding period when it is certain that such grant and input tax credit recoveries will be received. Cash and cash equivalents include highly liquid investments with original terms to maturity of 90 days or less at the date of purchase. For all periods presented cash and cash equivalents consisted entirely of cash. The Company is engaged in research and development work. Research and development costs are charged as operating expense of the Company as incurred. ASC 280-10, “Disclosures about Segments of an Enterprise and Related Information”, establishes standards for the way that public business enterprises report information about operating segments in the Company’s financial statements. Operating segments are components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company’s does not have any reportable segments. All of its operations and assets are domiciled in Canada. Income taxes are computed in accordance with the provisions of ASC Topic 740, which requires, among other things, a liability approach to calculating deferred income taxes. The Company recognizes deferred tax liabilities and assets for the expected future tax consequences of events that have been recognized in its financial statements or tax returns. Under this method, deferred tax liabilities and assets are determined based on the difference between the financial statement carrying amounts and tax bases of assets and liabilities using enacted tax rates in effect in the years in which the differences are expected to reverse. The Company is required to make certain estimates and judgments about the application of tax law, the expected resolution of uncertain tax positions and other matters. In the event that uncertain tax positions are resolved for amounts different than the Company’s estimates, or the related statutes of limitations expire without the assessment of additional income taxes, the Company will be required to adjust the amounts of related assets and liabilities in the period in which such events occur. Such adjustment may have a material impact on Bionik’s income tax provision and results of operations. ASC Topic 820 defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. Included in the ASC Topic 820 framework is a three level valuation inputs hierarchy with Level 1 being inputs and transactions that can be effectively fully observed by market participants spanning to Level 3 where estimates are unobservable by market participants outside of the Company and must be estimated using assumptions developed by the Company. The Company discloses the lowest level input significant to each category of asset or liability valued within the scope of ASC Topic 820 and the valuation method as exchange, income or use. The Company uses inputs which are as observable as possible and the methods most applicable to the specific situation of each company or valued item. The carrying amounts reported in the balance sheets for cash and cash equivalents, other receivables, accounts payable and accrued liabilities, convertible secured promissory note and due to / from related parties approximate fair value because of the short period of time between the origination of such instruments and their expected realization and their current market rates of interest. Per ASC Topic 820 framework these are considered Level 2 inputs where inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. For the loans payable, the Company believes the carrying value of the loans payable approximates fair value as the interest rates are market rates. There were no assets or liabilities measured at fair value on a recurring basis as of December 31, 2014 nor March 31, 2014. The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company reviews the terms of convertible loans, equity instruments and other financing arrangements to determine whether there are embedded derivative instruments, including embedded conversion options that are required to be bifurcated and accounted for separately as a derivative financial instrument. Also, in connection with the issuance of financing instruments, the Company may issue freestanding options or warrants to employees and non-employees in connection with consulting or other services. These options or warrants may, depending on their terms, be accounted for as derivative instrument liabilities, rather than as equity. Derivative financial instruments are initially measured at their fair value. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported as charges or credits to income. To the extent that the initial fair values of the freestanding and/or bifurcated derivative instrument liabilities exceed the total proceeds received an immediate charge to income is recognized in order to initially record the derivative instrument liabilities at their fair value. The discount from the face value of the convertible debt or equity instruments resulting from allocating some or all of the proceeds to the derivative instruments, together with the stated rate of interest on the instrument, is amortized over the life of the instrument through periodic charges to income, using the effective interest method. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is reassessed at the end of each reporting period. If reclassification is required, the fair value of the derivative instrument, as of the determination date, is reclassified. Any previous charges or credits to income for changes in the fair value of the derivative instrument are not reversed. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within twelve months of the balance sheet date. Basic and diluted loss per share has been determined by dividing the net loss available to shareholders for the applicable period by the basic and diluted weighted average number of shares outstanding, respectively. The diluted weighted average number of shares outstanding is calculated as if all dilutive options had been exercised or vested at the later of the beginning of the reporting period or date of grant, using the treasury stock method. The dilutive effect of convertible loans is reflected in diluted weighted average number of shares using the if-converted method, when there is a dilutive effect. Loss per common share is computed by dividing the net loss by the weighted average number of shares of common shares outstanding during the period. Common share equivalents are excluded from the computation of diluted loss per share when their effect is anti-dilutive. The Company follows the ASC Topic 360, which requires that long-lived assets be reviewed for impairment whenever events or changes in circumstances indicate that the assets’ carrying amounts may not be recoverable. In performing the review for recoverability, if future undiscounted cash flows (excluding interest charges) from the use and ultimate disposition of the assets are less than their carrying values, an impairment loss represented by the difference between its fair value and carrying value, is recognized. When properties are classified as held for sale they are recorded at the lower of the carrying amount or the expected sales price less costs to sell. “Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements (“ASU 2014-10”) issued in June 2014, ASU 2014-10 eliminated the distinction of a development stage entity and certain related disclosure requirements, including the elimination of inception-to-date information on the statements of operations, cash flows and stockholders’ equity. The amendments in ASU 2014-10 are effective prospectively for annual reporting periods beginning after December 15, 2014, and interim periods within those annual periods, however early adoption is permitted. The Company adopted ASU 2014-10 for its financial statements and accordingly has removed the inception-to-date information. “Comprehensive Income (Topic 220): Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income”, (“ASU 2013-2”) issued in February 2013 requires entities to disclose additional information for items reclassified out of accumulated other comprehensive income (“AOCI”). For items reclassified out of AOCI and into net income in their entirety, entities are required to disclose the effect of the reclassification on each affected line item of net income. For AOCI reclassification items that are not reclassified in their entirety into net income, a cross reference to other required U.S. GAAP disclosures is required. This information may be provided either in the notes or parenthetically on the face of the statement that reports net income, provided that all the information is disclosed in a single location. However, an entity is prohibited from providing this information parenthetically on the face of the statement that reports net income, if it has items that are not reclassified in their entirety into net income. The guidance is effective for annual and interim reporting periods beginning after December 15, 2012. The adoption of this standard did not have a material impact on the financial statements of the Company. “Income Taxes (Topic - 740): Presentation of an Unrecognized Tax Benefit when a Net Operating Loss Carry-forward, a Similar Tax Loss, or a Tax Credit Carry-forward Exists” (“ASU 2013-11”) issued in July 2013 provides guidance on how to present an unrecognized tax benefit. The guidance is effective for annual periods beginning after December 15, 2013. On May 28, 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers (Topic 606)”. The standard outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance. The accounting standard is effective for annual reporting periods (including interim reporting periods within those periods) beginning after December 15, 2016. Early adoption is not permitted. The impact on the Company’s Financial Statements of adopting ASU 2014-09 is being assessed by management. On August 27, 2014, the FASB issued a new financial accounting standard on going concern, ASU No. 2014-15, “Presentation of Financial Statements – Going Concern (Sub-Topic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern.” The standard provides guidance about management’s responsibility to evaluate whether there is a substantial doubt about the organization’s ability to continue as a going concern. The amendments in this Update apply to all companies. They become effective in the annual period ending after December 15, 2016, with early application permitted. The impact on the Company’s Financial Statements of adopting ASU 2014-15 is being assessed by management. Management does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the accompanying financial statements.

PREPAID EXPENSES AND OTHER RECE

PREPAID EXPENSES AND OTHER RECEIVABLES	6 Months Ended	9 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid Expense And Other Receivables [Text Block]	3. PREPAID EXPENSES AND OTHER RECEIVABLES June 30, December 31, $ $ Prepaid expenses and sundry receivables (Note 4) 57,603 18,172 Prepaid insurance 68,671 40,630 Sales taxes receivable (i) 38,079 22,328 164,353 81,130 i) Sales tax receivable represents net harmonized sales taxes (HST) input tax credits receivable from the Government of Canada.	3. PREPAID EXPENSES AND OTHER RECEIVABLES December 31, March 31, 2014 2014 $ $ Prepaid expenses and sundry receivables 18,172 11,700 Prepaid insurance 40,630 - IRAP Grant receivable (i) - 63,300 Investment tax credit receivable (ii) - 408,506 Sales taxes receivable (iii) 22,328 22,281 81,130 505,787 i) Industrial Research Assistance Program (“IRAP”) grant receivable is the value of claim receivable from the Government of Canada for recovery of eligible expenditures. The grant proceeds are recognized as ‘Other Income’ in the statements of operations and comprehensive loss, when received. ii) Investment tax credit receivable is the estimated Scientific Research and Experimental Development (“SR&ED”) claim receivable from the Government of Canada for input tax credits that are granted on qualifying SR&ED expenditures. The recovery, which was received in November 2014, is recognized as ‘Other Income’ in the statements of operations and comprehensive loss. iii) Sales tax receivable represents net harmonized sales taxes (HST) input tax credits receivable from the Government of Canada.

LOAN RECEIVABLE

LOAN RECEIVABLE	6 Months Ended
	Jun. 30, 2015
Receivables [Abstract]
Loans, Notes, Trade and Other Receivables Disclosure [Text Block]	4. LOAN RECEIVABLE During the period, the Company provided a loan to a third party in the amount of $ 150,000 6 repayable in 10 months 1,130

EQUIPMENT

EQUIPMENT	6 Months Ended	9 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment Disclosure [Text Block]	5. EQUIPMENT Equipment consisted of the following as at June 30, 2015 and December 31, 2014. June 30, 2015 December 31, 2014 Cost Accumulated Net Cost Accumulated Net $ $ $ $ $ $ Computers and electronics 141,686 53,865 87,821 77,650 27,438 50,212 Furniture and fixtures 24,909 8,496 16,413 24,909 7,325 17,584 Tools and parts 11,913 1,603 10,310 11,913 1,787 10,126 178,508 63,964 114,544 114,472 36,550 77,922 Equipment is recorded at cost less accumulated depreciation. Depreciation expense during the six and three month periods ended June 30, 2015 was $27,414 and $17,002, respectively (June 30, 2014 - $22,691 and $11,492).	4. EQUIPMENT December 31, 2014 March 31, 2014 Cost Accumulated Net Cost Accumulated Net $ $ $ $ $ $ Computers and electronics 77,650 27,438 50,212 - - - Furniture and fixtures 24,909 7,325 17,584 11,194 4,442 6,752 Tools and parts 11,913 1,787 10,126 - - - 114,472 36,550 77,922 11,194 4,442 6,752 Equipment is recorded at cost less accumulated depreciation. Depreciation expense during the nine month period ended December 31, 2014 was $ 34,036 1,349 1,772 2,330 Equipment is translated to U.S. Dollars using the rate of exchange prevailing at the balance sheet date. There were no disposals and $ 109,316 4,557 8,695

CONVERTIBLE SECURED PROMISSORY

CONVERTIBLE SECURED PROMISSORY NOTE	6 Months Ended	9 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Debt Disclosure [Abstract]
Debt Disclosure [Text Block]	6. CONVERTIBLE SECURED PROMISSORY NOTE On December 8, 2011, the Company received $61,500 CAD from a lender that at the time was non-interest bearing and had no specified terms of repayment. On February 28, 2012 the lender and the Company agreed to the terms of a Convertible Secured Promissory Note, which securitized the previous note plus an additional $60,000 CAD for a total principal amount of $121,500 CAD. The note was interest bearing at prime plus 1%, secured by a general security agreement and was to mature on the earlier of a qualifying financing event or February 28, 2014. The lender had an option to convert the principal plus accrued interest at a discount of 20% to the share price in the event of a qualifying financing event prior to February 28, 2014. The note matured on February 28, 2014, at this point the conversion option expired and the note became due on demand; however, no repayment was demanded. Upon the occurrence of the April financing (Note 8(i)) the Company agreed to honor the original conversion option and a beneficial conversion feature of $27,677 was recognized. As the note was due on demand the Company immediately recognized imputed interest of $27,677 in the condensed consolidated interim statement of operations and comprehensive loss. On May 9, 2014, the lender converted the note plus accrued interest into common shares based on the 20% discount to the $0.81 ($0.90 CAD) per share equity financing that was accomplished in April 2014 and the Company issued these pre-transaction shares in June, 2014 (see Note 8(iii)).	5. CONVERTIBLE SECURED PROMISSORY NOTE On December 8, 2011, the Company received $61,500 CAD from a lender that at the time was non-interest bearing and had no specified terms of repayment. On February 28, 2012 the lender and the Company agreed to the terms of a Convertible Secured Promissory Note, which securitized the previous note plus an additional $60,000 CAD for a total principal amount of $121,500 CAD. The note bears interest at prime plus 1 The lender had an option to convert the principal plus accrued interest at a discount of 20% to the share price in the event of a qualifying financing The Company determined that a market interest rate for similar debt would be approximately 10 105,262 16,238 27,677 55,647 3,939 7,282 The note matured on February 28, 2014, at this point the conversion option expired and the note became due on demand; however, no repayment was demanded. Upon the occurrence of the April 2014 financing (Note 8(x)) the Company agreed to honor the original conversion option and a beneficial conversion feature of $ 27,677 On May 9, 2014, the lender converted the note plus accrued interest in to common shares based on the 20 0.81

LOANS PAYABLE

LOANS PAYABLE	9 Months Ended
	Dec. 31, 2014
Loans Payable [Abstract]
Loans Payable Disclosure [Text Block]	6. LOANS PAYABLE December 31, 2014 March 31, 2014 $ $ a) Lieberman Family Trust The loan carried interest of 10% per annum and was payable within 90 days of demand or upon successful completion of a capital raise for $2,711,700 (CAD $3 million). Formerly secured by way of partial assignment of the Company’s entitlement to its SR&ED tax credit refund from the Government of Canada for the year ended March 31, 2014. - 27,141 b) Gaston-Dreyfus Remi The loan carried interest of 6% per annum and was payable on demand. The loan was secured by a general security agreement on all the assets of the Company. - 454,729 c) Parvez Patel/Huda The loan was unsecured, carried interest of 2% per annum and was repayable on demand or successful completion of capital raise for $5,694,570 (CAD $6.3 million). - 100,766 d) Pope & Co. The loan carried interest of 10% per annum and was payable within 90 days of demand or upon successful completion of a capital raise for $2,711,700 (CAD $3 million) by no later than June 30, 2014. Formerly secured by way of partial assignment of the Company’s entitlement to its SR&ED tax credit refund from the Government of Canada for the year ended March 31, 2014. - 189,510 - 772,146 (a) During the nine month period ended December 31, 2014, the loan from Lieberman Family Trust and accrued interest thereon was settled in exchange for 33,333 (b&c) During the nine month period ended December 31, 2014, the Company repaid the loan of $ 452,350 500,000 99,517 110,000 (d) During the nine month period ended December 31, 2014, the Company repaid loans for $ 180,940 200,000 12,138 13,417 349,522 0.23 On June 10, 2013, the Company agreed to the terms of a secured loan for $ 241,185 10 Under the terms of the loan agreement the lenders received an aggregate of 100,000 416,666 0.58 58,000 106,185 143,139 63,481 34,565 98,046 The loan was repaid on November 15, 2013, and the Company recognized accretion of the full amount of the discount of $ 98,046

RELATED PARTY TRANSACTIONS AND

RELATED PARTY TRANSACTIONS AND BALANCES	6 Months Ended	9 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	7. RELATED PARTY TRANSACTIONS AND BALANCES Due from related parties (a) As of June 30, 2015, the Company had advances receivable from the Chief Operating Officer (“COO”) and Chief Technology Officer (“CTO”) for $ 42,151 1 37,837 44,000 42,151 Issuance of shares to settle due to related party (b) During the nine months ended December 31, 2014, one advance amounting to $ 85,947 95,000 105,555 Accounts payable and accrued liabilities (c) As at June 30, 2015, $ 6,567 4,220 7,448 5,930 22,115 8,893	7. RELATED PARTY TRANSACTIONS AND BALANCES Due from related parties (a) As of December 31, 2014, the Company has advances receivable from the Chief Operating Officer (“COO”) and Chief Technology Officer (“CTO”) for $ 44,986 149,899 1 37,837 44,000 Issuance of shares to settle due to related party (b) During the nine months ended December 31, 2014, one advance amounting to $ 85,947 105,555 Accounts payable and accrued liabilities (c) As at December 31, 2014 there is $ 4,220 16,235 5,930 (d) As at December 31, 2014 there is $Nil (March 31, 2014 - $ 48,673

SHARE CAPITAL

SHARE CAPITAL	6 Months Ended	9 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	8. SHARE CAPITAL June 30, 2015 December 31, 2014 Number of $ Number of $ Exchangeable Shares: Balance at beginning of period 49,737,096 49,737 36,621,885 36,622 Shares issued for services (v) 262,904 263 - - Shares issued under private placement - - (i) 10,792,335 10,792 Shares issued on conversion and settlement of debt - - (ii)(iii) 1,012,142 1,012 Shares issued on the exercise of options - - (iv) 1,310,734 1,311 Balance at end of the period 50,000,000 50,000 49,737,096 49,737 Common Shares Balance at beginning of the period - - - - Shares issued as Merger consideration (vii) 6,000,063 6,000 - - Shares issued under private placement (v)-(xii) 16,408,250 16,408 - - Balance at end of the period 22,408,313 22,408 - - TOTAL COMMON SHARES 72,408,313 72,408 - - (i) In April, 2014, the Company completed a private placement issuing 10,792,335 0.24 2,590,160 11,609 (ii) In May 2014, the Company issued 436,908 115,223 (iii) In June, 2014, the Company issued 575,234 124,523 20 (iv) In June 2014, the Company issued 1,310,734 228,875 (v) On February 25, 2015, 262,904 241,185 210,323 314,560 320,000 (vi) Concurrently with the closing of the Merger on February 26, 2015, the Company issued 7,735,750 6,188,600 500,000 0.80 Each Unit consists of one common share of the Company, and a warrant to purchase one common share of the Company at an exercise price of $1.40 per share exercisable for 4 years. 848,822 773,575 0.80 4 (vii) Immediately following the Merger and the First Closing, 6,000,063 7,735,750 50,000,000 100 (viii) On March 27, 2015, the Company issued 1,212,500 970,000 Each Unit consisted of one common share of the Company, and a warrant to purchase one common share of the Company at an exercise price of $1.40 per share exercisable for 4 years. 141,100 121,250 0.80 4 (ix) On March 31 2015, the Company issued 891,250 713,000 Each Unit consisted of one common share of the Company, and a warrant to purchase one common share of the Company at an exercise price of $1.40 per share exercisable for 4 years. 92,690 89,125 0.80 4 (x) On April 21, 2015, the Company issued 3,115,000 2,492,000 Each Unit consisted of one common share of the Company, and a warrant to purchase one common share of the Company at an exercise price of $1.40 per share exercisable for 4 years. 338,960 311,500 0.80 4 (xi) On May 27, 2015, the Company issued 1,418,750 1,135,000 Each Unit consisted of one common share of the Company, and a warrant to purchase one common share of the Company at an exercise price of $1.40 per share exercisable for 4 years. 151,975 141,875 0.80 4 (xii) On June 30, 2015, the Company issued 2,035,000 1,628,000 211,656 203,500 0.80 4 Special Voting Preferred Share In connection with the Merger (Note 1), on February 26, 2015, the Company entered into a voting and exchange trust agreement (the “Trust Agreement”). Pursuant to the Trust Agreement, the Company issued one Special Voting Preferred Share to the Trustee, and the parties created a trust for the Trustee to hold the Special Voting Preferred Share for the benefit of the holders of the Exchangeable Shares (the “Beneficiaries”). Pursuant to the Trust Agreement, the Beneficiaries will have voting rights in the Company equivalent to what they would have had they received shares of common stock in the same amount as the Exchangeable Shares held by the Beneficiaries. In connection with the Merger and the Trust Agreement, effective February 20, 2015, the Company filed a certificate of designation of the Special Voting Preferred Share (the “Special Voting Certificate of Designation”) with the Delaware Secretary of State. Pursuant to the Special Voting Certificate of Designation, one share of the Company’s blank check preferred stock was designated as Special Voting Preferred Share. The Special Voting Preferred Share entitles the Trustee to exercise the number of votes equal to the number of Exchangeable Shares outstanding on a one-for-one basis during the term of the Trust Agreement. The Special Voting Preferred Share is not entitled to receive any dividends or to receive any assets of the Company upon liquidation, and is not convertible into common shares of the Company. The voting rights of the Special Voting Preferred Share will terminate pursuant to and in accordance with the Trust Agreement. The Special Voting Preferred Share will be automatically cancelled at such time as no Exchangeable Shares are held by a Beneficiary.	8. CAPITAL STOCK Number of Stated Balance, April 1, 2012 (i) 9,000,000 5 Issued under private placement (ii) 291,667 170,815 Issued on settlement of debt relating to prior period services (iii) 200,000 117,192 Issued under private placement (iv) 895,834 519,420 Cancellation of common stock (v) (250,000) - Issued under private placement (vi) 437,500 256,016 Issued under private placement (vii) 383,333 232,546 Issued under private placement (viii) 516,666 308,183 Share issue costs - (34,583) Balance, March 31, 2013 11,475,000 1,569,594 Issued under private placement (ix) 166,667 96,320 Share issue costs - (7,329) Balance, March 31, 2014 11,641,667 1,658,585 Issued under private placement (x) 3,430,756 2,616,062 Issued on conversion and settlement of debt (xi), (xii), (xiii) 321,748 239,746 Issued on the exercise of options (xiv) 416,667 335,060 Share issue costs (x) - (11,609) Balance December 31, 2014 15,810,838 4,837,844 (i) The opening balance consists of 7,750,000 2 1,000,000 250,000 1,250,000 3 (ii) In May, 2012, the Company issued through a private placement, 291,667 0.59 0.60 170,815 (iii) In May, 2012, 200,000 117,192 (iv) In June, 2012, the Company issued through a private placement, 895,834 0.58 0.60 519,420 (v) In August, 2012, 125,000 250,000 (vi) In September, 2012, the Company issued through a private placement, 437,500 0.59 0.60 256,016 (vii) In December, 2012, the Company issued through a private placement, 383,333 0.61 0.60 232,546 (viii) In March 2013, the Company issued through a private placement, 516,666 0.60 0.60 308,183 58,846 (ix) In June, 2013, the Company issued through a private placement, 166,667 0.58 0.60 96,320 (x) In April, 2014, the Company completed a private placement issuing 3,182,978 0.82 0.90 2,616,062 2,864,680 247,778 11,609 (xi) In May 2014, the Company issued 105,555 87,638 95,000 (xii) In May 2014, the Company issued 33,333 27,585 30,000 (xiii) In June, 2014, the Company issued 182,860 124,523 131,659 20 0.68 0.90 (xiv) In June 2014, the Company issued 416,667 228,875 250,000 106,185

STOCK OPTIONS

STOCK OPTIONS	6 Months Ended	9 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	9. STOCK OPTIONS The purpose of the Company’s stock option plan, is to attract, retain and motivate persons of training, experience and leadership to the Company, including their directors, officers and employees, and to advance the interests of the Company by providing such persons with the opportunity, through share options, to acquire an increased proprietary interest in the Company. Options may be granted in respect of authorized and unissued shares, provided that the aggregate number of shares reserved for issuance upon the exercise of all Options granted under the Plan, shall not exceed 10,800,000 On April 11, 2014 and June 20, 2014 the Company issued 657,430 264,230 0.165 0.23 125,824 657,430 531,606 264,230 230,930 118,957 104,853 93,025 45,909 67,616 22,670 19,165 9,225 14,194 5,554 On July 1, 2014, the Company issued 2,972,592 0.23 7 1,259,487 On February 17, 2015 the Company issued 314,560 0.23 136,613 52,428 60,451 9,681 February 17, July 1, June 20, April 11, Expected life in years 5 4.35 6.32 4.14 Risk free rate 1.59 % 1.59 % 1.59 % 1.59 % Dividend yield 0 % 0 % 0 % 0 % Forfeiture rate 0 % 0 % 0 % 0 % Expected volatility 114 % 114 % 114 % 114 % Number of Options Weighted-Average Outstanding, December 31, 2013 1,310,665 0.19 Exercised (1,310,665) 0.19 Issued 3,894,252 0.22 Cancelled (125,824) 0.17 Outstanding, December 31, 2014 3,768,428 0.22 Cancelled as a result of Merger (3,768,428) 0.22 Re-issued as part of Merger 3,768,428 0.22 Issued 314,560 0.23 Cancelled (157,281) 0.23 Outstanding, June 30, 2015 3,925,707 0.22 Exercise Price ($) Number of Options Expiry Date Number of 0.165 531,606 April 1, 2021 354,404 0.23 159,377 June 20, 2021 123,727 0.23 2,972,592 July 1, 2021 2,972,592 0.23 262,132 February 17, 2022 104,857 3,925,707 3,555,580	9. STOCK OPTIONS The Company has a stock option plan, the purpose of which is to attract, retain and motivate persons connected to the Company, including their directors, officers and employees, and to advance the interests of the Company by providing such persons with the opportunity, through share options, to acquire an increased proprietary interest in the Company. Options may be granted in respect of authorized and unissued shares, provided that the aggregate number of shares reserved for issuance upon the exercise of all Options granted under the Plan, shall not exceed eight ( 8 On June 10, 2013, the Company issued 416,667 0.52 0.60 106,185 On April 11, 2014 and June 20, 2014 the Company issued 209,000 84,000 0.52 0.60 0.77 0.90 153,348 61,142 40,000 112,573 On July 1, 2014, the Company issued a further 945,000 0.77 0.90 6,000,000 719,835 Expected life 7 years Risk free rate 1.59 % Dividend yield 0 % Forfeiture rate 0 % Volatility (based upon similar public companies) 114 % Number of Weighted Average Weighted Average options Exercise Price Remaining Contract Life # $ (Years) Outstanding, March 31, 2012 and 2013 - - - Granted during the year 416,667 0.52 - Outstanding March 31, 2014 416,667 0.52 0.20 Exercised during the period (416,667) 0.52 - Granted during the period 1,238,000 0.73 7 Cancelled during the period (40,000) 0.52 - Outstanding, December 31, 2014 1,198,000 0.74 6.72

WARRANTS

WARRANTS	6 Months Ended
	Jun. 30, 2015
Warrants and Rights Note Disclosure [Abstract]
Shareholders Equity And Share Based Payments Stock Warrant [Text Block]	10. WARRANTS Number of Weighted-Average Outstanding and exercisable, December 31, 2014 and 2013 - - Issued 18,049,075 1.35 Outstanding and exercisable, June 30, 2015 18,049,075 1.35 Exercise Number of Expiry Date 1.40 Note 8(vi) 7,735,750 February 26, 2019 0.80 Note 8(vi) 773,575 February 26, 2019 1.40 Note 8(viii) 1,212,500 March 27, 2019 0.80 Note 8(viii) 121,250 March 27, 2019 1.40 Note 8(ix) 891,250 March 31, 2019 0.80 Note 8(ix) 89,125 March 31, 2019 1.40 Note 8(x) 3,115,000 April 21, 2019 0.80 Note 8(x) 311,500 April 21, 2019 1.40 Note 8(xi) 1,418,750 May 27, 2019 0.80 Note 8(xi) 141,875 May 27, 2019 1.40 Note 8(xii) 2,035,000 June 30, 2019 0.80 Note 8(xii) 203,500 June 30, 2019 18,049,075 In 2014 the Company repaid loans of $ 180,940 12,138 349,522 0.23

CONTINGENCIES

CONTINGENCIES	6 Months Ended	9 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	11. CONTINGENCIES From time to time, the Company may be involved in a variety of claims, suits, investigations and proceedings arising in the ordinary course of our business, collections claims, breach of contract claims, labor and employment claims, tax and other matters. Although claims, suits, investigations and proceedings are inherently uncertain and their results cannot be predicted with certainty, the Company believes that the resolution of current pending matters will not have a material adverse effect on its business, financial position, results of operations or cash flow. Regardless of the outcome, litigation can have an adverse impact on the Company because of legal costs, diversion of management resources and other factors.	CONTINGENCIES From time to time, the Company may be involved in a variety of claims, suits, investigations and proceedings arising in the ordinary course of our business, collections claims, breach of contract claims, labor and employment claims, tax and other matters. Although claims, suits, investigations and proceedings are inherently uncertain and their results cannot be predicted with certainty, the Company believes that the resolution of current pending matters will not have a material adverse effect on its business, financial position, results of operations or cash flow. Regardless of the outcome, litigation can have an adverse impact on the Company because of legal costs, diversion of management resources and other factors.

INCOME TAXES

INCOME TAXES	9 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	11. INCOME TAXES 9 month periods ended Years ended December 31, 2014 March 31, 2014 March 31, 2013 $ $ $ Components of net loss before income taxes consists of the following: U.S. - - - Canada (2,464,747) (1,451,769) (937,059) (2,464,747) (1,451,769) (937,059) 2014 2014 2013 $ $ $ Net loss before recovery of income taxes (2,464,747) (1,451,769) (937,059) Statutory rate 26.50 % 26.50 % 26.50 % Expected income tax recovery (653,158) (384,719) (248,321) Other basis adjustment (29,109) (6,966) (8,576) Non-deductible expenses 193,305 148,936 (38,493) Change in valuation allowance 488,962 242,749 295,390 Recovery of income taxes - - - 2014 2014 2013 $ $ $ Deferred tax assets Current - 403 - Valuation allowance - (403) - - - - Long-term $ $ $ Unrealized tax credits - 19,591 19,721 Property and equipment 36,940 23,985 - Share issue costs 7,137 6,461 7,228 SR&ED pool 162,350 - - Other 18,621 - - Net operating losses 812,522 529,889 310,228 Valuation allowance (1,037,570) (579,926) (337,177) - - -

RISK MANAGEMENT

RISK MANAGEMENT	6 Months Ended	9 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Risks and Uncertainties [Abstract]
Concentration Risk Disclosure [Text Block]	12. RISK MANAGEMENT The Company’s cash balances are maintained in two banks in Canada and a Canadian Bank subsidiary in the US. Deposits held in banks in Canada are insured up to $100,000 CAD per depositor for each bank by The Canada Deposit Insurance Corporation, a federal crown corporation. Actual balances at times may exceed these limits. Interest Rate Risk Interest rate risk is the risk that the value of a financial instrument might be adversely affected by a change in the interest rates. The Company settled its loans payable and convertible secured promissory note; therefore, it retains minimal exposure to fluctuations in the market interest rate. In seeking to minimize the risks from interest rate fluctuations, the Company manages exposure through its normal operating and financing activities. Liquidity Risk Liquidity risk is the risk that the Company will incur difficulties meeting its financial obligations as they are due. The Company’s approach to managing liquidity is to ensure, as far as possible, that it will have sufficient liquidity to meet its liabilities when due. Accounts payable and accrued liabilities are due within the current operating period. The Company has funded its operations through the issuance of capital stock, convertible debt and loans in addition to grants and investment tax credits received from the Government of Canada. Based on management’s assessment of the Company’s cash flow needs, management believes the Company has sufficient cash to sustain operations for an additional 12 month period.	12. RISK MANAGEMENT The Company’s cash balances are maintained in various banks in Canada. Deposits held in banks in Canada are insured up to $ 100,000 Interest Rate Risk Interest rate risk is the risk that the value of a financial instrument might be adversely affected by a change in the interest rates. The Company settled its loans payable and convertible secured promissory note; therefore, it retains minimal exposure to fluctuations in the market interest rate. In seeking to minimize the risks from interest rate fluctuations, the Company manages exposure through its normal operating and financing activities. Liquidity Risk Liquidity risk is the risk that the Company will incur difficulties meeting its financial obligations as they are due. The Company’s approach to managing liquidity is to ensure, as far as possible, that it will have sufficient liquidity to meet its liabilities when due. Accounts payable and accrued liabilities are due within the current operating period. The Company has funded its operations through the issuance of capital stock, convertible debt and loans in addition to grants and investment tax credits received from the Government of Canada. During the nine months ended December 31, 2014, the Company raised gross proceeds of $ 2,616,062 228,875 Based on management’s assessment of the Company’s cash flow, and the financing completed subsequent to period end (Note 13(c)), management believes the Company has sufficient cash to sustain operations for an additional 12 month period.

SUBSEQUENT EVENT

SUBSEQUENT EVENT	6 Months Ended	9 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Subsequent Events [Abstract]
Subsequent Events [Text Block]	13. SUBSEQUENT EVENT Subsequent to June 30, 2015, the Company entered into service agreements with unrelated companies that result in a commitment to issue up to an aggregate 102,500 135,000	13. SUBSEQUENT EVENTS (a) On January 21, 2015, the Company received a $ 500,000 5 6,000,000 (b) On February 25, 2015, 262,904 241,185 250,000 100,000 83,574 (c) On February 26, 2015, the Company (“Bionik Canada”) finalized a Share Exchange Agreement with Bionik Laboratories Corp. (“BLC” formerly known as Drywave Technologies Inc.) whereby Bionik Canada issued 50,000,000 100 After giving effect to the Acquisition Transaction, BLC commenced operations through Bionik Canada which by virtue of the Acquisition Transaction is now a reporting issuer through BLC’s listing on the OTC Pink marketplace. As a result of the shareholders of Bionik Canada having a controlling interest in BLC subsequent to the Acquisition Transaction, for accounting purposes the Acquisition Transaction does not constitute a business combination. The transaction has been accounted for as a recapitalization of BLC with Bionik Canada being the accounting acquirer even though the legal acquirer is Bionik. Concurrently with the closing of the Acquisition Transaction on February 26, 2015, BLC issued 7,735,750 6,188,600 0.80 Each Unit consists of one common share of BLC, and a warrant to purchase one common share of BLC at an exercise price of $1.40 per share exercisable for 4 years. 848,822 773,575 0.80 4 (d) Immediately following the Acquisition Transaction and the First Closing, 6,000,000 7,735,750 100 (e) On March 27, 2015, BLC issued 1,212,500 970,000 Each Unit consisted of one common share of BLC, and a warrant to purchase one common share of BLC at an exercise price of $1.40 per share exercisable for 4 years. 141,100 121,250 0.80 4 (f) On March 31, 2015, BLC issued 891,250 713,000 Each Unit consisted of one common share of BLC, and a warrant to purchase one common share of BLC at an exercise price of $1.40 per share exercisable for 4 years 97,098 89,125 0.80 4 (g) On April 21, 2015, BLC sold to accredited investors a fourth closing of the Offering, 3,115,000 2,492,000 Each Unit consisted of one common share of BLC, and a warrant to purchase one common share of BLC at an exercise price of $1.40 per share exercisable for 4 years 338,960 311,500 0.80 4 (h) On February 17, 2015 BLC issued 100,000 0.77 314,560 0.23 136,613 (i) Subsequent to year end the Company lent a third party $ 150,000 5 18 months (j) Upon the close of the Acquisition Transaction, the condition was met on the 945,000 90 2,972,592 0.23 1,259,487 Further, as a result of the Acquisition Transaction, the options issued on April 11, 2014 and June 20, 2014 (Note 9) were amended to constitute 531,606 264,230 0.165 0.23 531,606 264,230 230,930 118,957

SIGNIFICANT ACCOUNTING POLICI22

SIGNIFICANT ACCOUNTING POLICIES (Policies)	6 Months Ended	9 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Accounting Policies [Abstract]
Unaudited Condensed Consolidated Interim Financial Statements [Policy Text Block]	Unaudited Condensed Consolidated Interim Financial Statements These unaudited condensed consolidated interim financial statements have been prepared on the same basis as the annual audited financial statements and should be read in conjunction with those annual audited financial statements filed on Form 10-K for the year ended December 31, 2014. In the opinion of management, these unaudited condensed consolidated interim financial statements reflect adjustments, necessary to present fairly the Company's financial position, results of operations and cash flows for the periods shown. The results of operations for such periods are not necessarily indicative of the results expected for a full year or for any future period.
Use of Estimates, Policy [Policy Text Block]		Use of Estimates The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates, and changes in these estimates are recorded when known. Significant estimates made by management include: investment tax credit receivable (see note 3) and the valuation allowance for deferred tax assets.
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Foreign Currency Translation On April 1, 2015, Bionik Canada and Bionik Acquisition Inc. changed its functional currency from the Canadian Dollar to the U.S. Dollar. This reflects the fact that the majority of the Company’s business is influenced by an economic environment denominated in U.S. currency as well the Company anticipates revenues to be earned in U.S. dollars. The change in accounting treatment is applied prospectively. The functional currency is separately determined for the Company and each of its subsidiaries, and is used to measure the financial position and operating results. The functional currency of the Company and its wholly-owned subsidiaries is the U.S. dollar. Transactions denominated in a currency other than the functional currency are recorded on initial recognition at the exchange rate at the date of the transaction. After initial recognition, monetary assets and liabilities denominated in foreign currency are translated at the end of each reporting period into the functional currency at the exchange rate at that date. Exchange differences are recognized in profit or loss. Non-monetary assets and liabilities measured at cost are translated at the exchange rate at the date of the transaction.	Foreign Currency Translation The Company’s functional currency is the Canadian dollar and its reporting currency is the US dollar. The financial statements have been translated into US dollars in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 830. All assets and liabilities with Canadian dollars as functional currency are translated at the exchange rate on the balance sheet date, shareholders' equity and share issuances are translated at the historical rates and the statements of operations and cash flows are translated at the average exchange rate for the year. The resulting translation adjustments are reported under comprehensive income as a separate component of shareholders’ equity (deficiency).
Property, Plant and Equipment, Policy [Policy Text Block]		Equipment Equipment is recorded at cost. Depreciation is computed using the declining balance method, over the estimated useful lives of these assets. The costs of improvements that extend the life of equipment are capitalized. All ordinary repair and maintenance costs are expensed as incurred. Computers and electronics 50 Furniture and fixtures 20 Tools and parts 20
Revenue Recognition, Policy [Policy Text Block]		Revenue Recognition The Company has yet to recognize any revenue. The Company intends to record revenue when it is realized, or realizable and earned. The Company will consider revenue to be realized, or realizable and earned, when the following revenue recognition requirements are met: persuasive evidence of an arrangement exists; the products or services have been accepted by the customer via delivery or acceptance; the sales price is fixed or determinable; and collectability is reasonably assured.
Government Grant and Input Tax Credit Recoveries [Policy Text Block]		Government Grant and Input Tax Credit Recoveries The Company receives certain grant and input tax credit recoveries from the Canadian government in compensation for eligible expenditures. These are presented as other income in the statements of operations and comprehensive loss as they generally relate to a number of the Company’s operating expenses, such as salaries and benefits, research and development and professional and consulting fees. The recoveries are recognized in the corresponding period when it is certain that such grant and input tax credit recoveries will be received.
Cash and Cash Equivalents, Policy [Policy Text Block]		Cash and Cash Equivalents Cash and cash equivalents include highly liquid investments with original terms to maturity of 90 days or less at the date of purchase. For all periods presented cash and cash equivalents consisted entirely of cash.
Research and Development Expense, Policy [Policy Text Block]		Research and Development The Company is engaged in research and development work. Research and development costs are charged as operating expense of the Company as incurred.
Segment Reporting, Policy [Policy Text Block]		Segment Reporting ASC 280-10, “Disclosures about Segments of an Enterprise and Related Information”, establishes standards for the way that public business enterprises report information about operating segments in the Company’s financial statements. Operating segments are components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company’s does not have any reportable segments. All of its operations and assets are domiciled in Canada.
Income Tax, Policy [Policy Text Block]		Income Taxes Income taxes are computed in accordance with the provisions of ASC Topic 740, which requires, among other things, a liability approach to calculating deferred income taxes. The Company recognizes deferred tax liabilities and assets for the expected future tax consequences of events that have been recognized in its financial statements or tax returns. Under this method, deferred tax liabilities and assets are determined based on the difference between the financial statement carrying amounts and tax bases of assets and liabilities using enacted tax rates in effect in the years in which the differences are expected to reverse. The Company is required to make certain estimates and judgments about the application of tax law, the expected resolution of uncertain tax positions and other matters. In the event that uncertain tax positions are resolved for amounts different than the Company’s estimates, or the related statutes of limitations expire without the assessment of additional income taxes, the Company will be required to adjust the amounts of related assets and liabilities in the period in which such events occur. Such adjustment may have a material impact on Bionik’s income tax provision and results of operations.
Fair Value of Financial Instruments, Policy [Policy Text Block]		Fair Value of Financial Instruments ASC Topic 820 defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. Included in the ASC Topic 820 framework is a three level valuation inputs hierarchy with Level 1 being inputs and transactions that can be effectively fully observed by market participants spanning to Level 3 where estimates are unobservable by market participants outside of the Company and must be estimated using assumptions developed by the Company. The Company discloses the lowest level input significant to each category of asset or liability valued within the scope of ASC Topic 820 and the valuation method as exchange, income or use. The Company uses inputs which are as observable as possible and the methods most applicable to the specific situation of each company or valued item. The carrying amounts reported in the balance sheets for cash and cash equivalents, other receivables, accounts payable and accrued liabilities, convertible secured promissory note and due to / from related parties approximate fair value because of the short period of time between the origination of such instruments and their expected realization and their current market rates of interest. Per ASC Topic 820 framework these are considered Level 2 inputs where inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. For the loans payable, the Company believes the carrying value of the loans payable approximates fair value as the interest rates are market rates. There were no assets or liabilities measured at fair value on a recurring basis as of December 31, 2014 nor March 31, 2014.
Derivatives, Reporting of Derivative Activity [Policy Text Block]		Derivative Financial Instruments The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company reviews the terms of convertible loans, equity instruments and other financing arrangements to determine whether there are embedded derivative instruments, including embedded conversion options that are required to be bifurcated and accounted for separately as a derivative financial instrument. Also, in connection with the issuance of financing instruments, the Company may issue freestanding options or warrants to employees and non-employees in connection with consulting or other services. These options or warrants may, depending on their terms, be accounted for as derivative instrument liabilities, rather than as equity. Derivative financial instruments are initially measured at their fair value. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported as charges or credits to income. To the extent that the initial fair values of the freestanding and/or bifurcated derivative instrument liabilities exceed the total proceeds received an immediate charge to income is recognized in order to initially record the derivative instrument liabilities at their fair value. The discount from the face value of the convertible debt or equity instruments resulting from allocating some or all of the proceeds to the derivative instruments, together with the stated rate of interest on the instrument, is amortized over the life of the instrument through periodic charges to income, using the effective interest method. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is reassessed at the end of each reporting period. If reclassification is required, the fair value of the derivative instrument, as of the determination date, is reclassified. Any previous charges or credits to income for changes in the fair value of the derivative instrument are not reversed. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within twelve months of the balance sheet date.
Earnings Per Share, Policy [Policy Text Block]		Basic and Diluted Loss Per Share Basic and diluted loss per share has been determined by dividing the net loss available to shareholders for the applicable period by the basic and diluted weighted average number of shares outstanding, respectively. The diluted weighted average number of shares outstanding is calculated as if all dilutive options had been exercised or vested at the later of the beginning of the reporting period or date of grant, using the treasury stock method. The dilutive effect of convertible loans is reflected in diluted weighted average number of shares using the if-converted method, when there is a dilutive effect. Loss per common share is computed by dividing the net loss by the weighted average number of shares of common shares outstanding during the period. Common share equivalents are excluded from the computation of diluted loss per share when their effect is anti-dilutive.
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]		Impairment of Long-Lived Assets The Company follows the ASC Topic 360, which requires that long-lived assets be reviewed for impairment whenever events or changes in circumstances indicate that the assets’ carrying amounts may not be recoverable. In performing the review for recoverability, if future undiscounted cash flows (excluding interest charges) from the use and ultimate disposition of the assets are less than their carrying values, an impairment loss represented by the difference between its fair value and carrying value, is recognized. When properties are classified as held for sale they are recorded at the lower of the carrying amount or the expected sales price less costs to sell.
Recently Adopted Accounting Pronouncements [Policy Text Block]		Recently Adopted Accounting Pronouncements “Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements (“ASU 2014-10”) issued in June 2014, ASU 2014-10 eliminated the distinction of a development stage entity and certain related disclosure requirements, including the elimination of inception-to-date information on the statements of operations, cash flows and stockholders’ equity. The amendments in ASU 2014-10 are effective prospectively for annual reporting periods beginning after December 15, 2014, and interim periods within those annual periods, however early adoption is permitted. The Company adopted ASU 2014-10 for its financial statements and accordingly has removed the inception-to-date information. “Comprehensive Income (Topic 220): Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income”, (“ASU 2013-2”) issued in February 2013 requires entities to disclose additional information for items reclassified out of accumulated other comprehensive income (“AOCI”). For items reclassified out of AOCI and into net income in their entirety, entities are required to disclose the effect of the reclassification on each affected line item of net income. For AOCI reclassification items that are not reclassified in their entirety into net income, a cross reference to other required U.S. GAAP disclosures is required. This information may be provided either in the notes or parenthetically on the face of the statement that reports net income, provided that all the information is disclosed in a single location. However, an entity is prohibited from providing this information parenthetically on the face of the statement that reports net income, if it has items that are not reclassified in their entirety into net income. The guidance is effective for annual and interim reporting periods beginning after December 15, 2012. The adoption of this standard did not have a material impact on the financial statements of the Company.
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Issued Accounting Pronouncements On May 28, 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers (Topic 606)”. The standard outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance. The accounting standard is effective for annual reporting periods (including interim reporting periods within those periods) beginning after December 15, 2017. Early adoption is not permitted. The impact on the condensed interim financial statements of adopting ASU 2014-09 will be assessed by management. On August 27, 2014, the FASB issued a new financial accounting standard on going concern, ASU No. 2014-15, “Presentation of Financial Statements – Going Concern (Sub-Topic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern.” The standard provides guidance about management’s responsibility to evaluate whether there is a substantial doubt about the organization’s ability to continue as a going concern. The amendments in this Update apply to all companies. They become effective in the annual period ending after December 15, 2016, with early application permitted. The impact on the condensed interim financial statements of adopting ASU 2014-15 will be assessed by management. Management does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the accompanying condensed consolidated interim financial statements.	Recently Issued Accounting Pronouncements “Income Taxes (Topic - 740): Presentation of an Unrecognized Tax Benefit when a Net Operating Loss Carry-forward, a Similar Tax Loss, or a Tax Credit Carry-forward Exists” (“ASU 2013-11”) issued in July 2013 provides guidance on how to present an unrecognized tax benefit. The guidance is effective for annual periods beginning after December 15, 2013. On May 28, 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers (Topic 606)”. The standard outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance. The accounting standard is effective for annual reporting periods (including interim reporting periods within those periods) beginning after December 15, 2016. Early adoption is not permitted. The impact on the Company’s Financial Statements of adopting ASU 2014-09 is being assessed by management. Management does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the accompanying financial statements.

PREPAID EXPENSES AND OTHER RE23

PREPAID EXPENSES AND OTHER RECEIVABLES (Tables)	6 Months Ended	9 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]	June 30, December 31, $ $ Prepaid expenses and sundry receivables (Note 4) 57,603 18,172 Prepaid insurance 68,671 40,630 Sales taxes receivable (i) 38,079 22,328 164,353 81,130 i) Sales tax receivable represents net harmonized sales taxes (HST) input tax credits receivable from the Government of Canada.	December 31, March 31, 2014 2014 $ $ Prepaid expenses and sundry receivables 18,172 11,700 Prepaid insurance 40,630 - IRAP Grant receivable (i) - 63,300 Investment tax credit receivable (ii) - 408,506 Sales taxes receivable (iii) 22,328 22,281 81,130 505,787 i) Industrial Research Assistance Program (“IRAP”) grant receivable is the value of claim receivable from the Government of Canada for recovery of eligible expenditures. The grant proceeds are recognized as ‘Other Income’ in the statements of operations and comprehensive loss, when received. ii) Investment tax credit receivable is the estimated Scientific Research and Experimental Development (“SR&ED”) claim receivable from the Government of Canada for input tax credits that are granted on qualifying SR&ED expenditures. The recovery, which was received in November 2014, is recognized as ‘Other Income’ in the statements of operations and comprehensive loss. iii) Sales tax receivable represents net harmonized sales taxes (HST) input tax credits receivable from the Government of Canada.

EQUIPMENT (Tables)

EQUIPMENT (Tables)	6 Months Ended	9 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment [Table Text Block]	Equipment consisted of the following as at June 30, 2015 and December 31, 2014. June 30, 2015 December 31, 2014 Cost Accumulated Net Cost Accumulated Net $ $ $ $ $ $ Computers and electronics 141,686 53,865 87,821 77,650 27,438 50,212 Furniture and fixtures 24,909 8,496 16,413 24,909 7,325 17,584 Tools and parts 11,913 1,603 10,310 11,913 1,787 10,126 178,508 63,964 114,544 114,472 36,550 77,922	December 31, 2014 March 31, 2014 Cost Accumulated Net Cost Accumulated Net $ $ $ $ $ $ Computers and electronics 77,650 27,438 50,212 - - - Furniture and fixtures 24,909 7,325 17,584 11,194 4,442 6,752 Tools and parts 11,913 1,787 10,126 - - - 114,472 36,550 77,922 11,194 4,442 6,752

LOANS PAYABLE (Tables)

LOANS PAYABLE (Tables)	9 Months Ended
	Dec. 31, 2014
Loans Payable [Abstract]
Schedule of Loans payable [Table Text Block]	December 31, 2014 March 31, 2014 $ $ a) Lieberman Family Trust The loan carried interest of 10% per annum and was payable within 90 days of demand or upon successful completion of a capital raise for $2,711,700 (CAD $3 million). Formerly secured by way of partial assignment of the Company’s entitlement to its SR&ED tax credit refund from the Government of Canada for the year ended March 31, 2014. - 27,141 b) Gaston-Dreyfus Remi The loan carried interest of 6% per annum and was payable on demand. The loan was secured by a general security agreement on all the assets of the Company. - 454,729 c) Parvez Patel/Huda The loan was unsecured, carried interest of 2% per annum and was repayable on demand or successful completion of capital raise for $5,694,570 (CAD $6.3 million). - 100,766 d) Pope & Co. The loan carried interest of 10% per annum and was payable within 90 days of demand or upon successful completion of a capital raise for $2,711,700 (CAD $3 million) by no later than June 30, 2014. Formerly secured by way of partial assignment of the Company’s entitlement to its SR&ED tax credit refund from the Government of Canada for the year ended March 31, 2014. - 189,510 - 772,146 (a) During the nine month period ended December 31, 2014, the loan from Lieberman Family Trust and accrued interest thereon was settled in exchange for 33,333 (b&c) During the nine month period ended December 31, 2014, the Company repaid the loan of $ 452,350 500,000 99,517 110,000 (d) During the nine month period ended December 31, 2014, the Company repaid loans for $ 180,940 200,000 12,138 13,417 349,522 0.23

SHARE CAPITAL (Tables)

SHARE CAPITAL (Tables)	6 Months Ended	9 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Stockholders' Equity Note [Abstract]
Schedule of Stockholders Equity [Table Text Block]	June 30, 2015 December 31, 2014 Number of $ Number of $ Exchangeable Shares: Balance at beginning of period 49,737,096 49,737 36,621,885 36,622 Shares issued for services (v) 262,904 263 - - Shares issued under private placement - - (i) 10,792,335 10,792 Shares issued on conversion and settlement of debt - - (ii)(iii) 1,012,142 1,012 Shares issued on the exercise of options - - (iv) 1,310,734 1,311 Balance at end of the period 50,000,000 50,000 49,737,096 49,737 Common Shares Balance at beginning of the period - - - - Shares issued as Merger consideration (vii) 6,000,063 6,000 - - Shares issued under private placement (v)-(xii) 16,408,250 16,408 - - Balance at end of the period 22,408,313 22,408 - - TOTAL COMMON SHARES 72,408,313 72,408 - - (i) In April, 2014, the Company completed a private placement issuing 10,792,335 0.24 2,590,160 11,609 (ii) In May 2014, the Company issued 436,908 115,223 (iii) In June, 2014, the Company issued 575,234 124,523 20 (iv) In June 2014, the Company issued 1,310,734 228,875 (v) On February 25, 2015, 262,904 241,185 210,323 314,560 320,000 (vi) Concurrently with the closing of the Merger on February 26, 2015, the Company issued 7,735,750 6,188,600 500,000 0.80 Each Unit consists of one common share of the Company, and a warrant to purchase one common share of the Company at an exercise price of $1.40 per share exercisable for 4 years. 848,822 773,575 0.80 4 (vii) Immediately following the Merger and the First Closing, 6,000,063 7,735,750 50,000,000 100 (viii) On March 27, 2015, the Company issued 1,212,500 970,000 Each Unit consisted of one common share of the Company, and a warrant to purchase one common share of the Company at an exercise price of $1.40 per share exercisable for 4 years. 141,100 121,250 0.80 4 (ix) On March 31 2015, the Company issued 891,250 713,000 Each Unit consisted of one common share of the Company, and a warrant to purchase one common share of the Company at an exercise price of $1.40 per share exercisable for 4 years. 92,690 89,125 0.80 4 (x) On April 21, 2015, the Company issued 3,115,000 2,492,000 Each Unit consisted of one common share of the Company, and a warrant to purchase one common share of the Company at an exercise price of $1.40 per share exercisable for 4 years. 338,960 311,500 0.80 4 (xi) On May 27, 2015, the Company issued 1,418,750 1,135,000 Each Unit consisted of one common share of the Company, and a warrant to purchase one common share of the Company at an exercise price of $1.40 per share exercisable for 4 years. 151,975 141,875 0.80 4 (xii) On June 30, 2015, the Company issued 2,035,000 1,628,000 211,656 203,500 0.80 4	Number of Stated Balance, April 1, 2012 (i) 9,000,000 5 Issued under private placement (ii) 291,667 170,815 Issued on settlement of debt relating to prior period services (iii) 200,000 117,192 Issued under private placement (iv) 895,834 519,420 Cancellation of common stock (v) (250,000) - Issued under private placement (vi) 437,500 256,016 Issued under private placement (vii) 383,333 232,546 Issued under private placement (viii) 516,666 308,183 Share issue costs - (34,583) Balance, March 31, 2013 11,475,000 1,569,594 Issued under private placement (ix) 166,667 96,320 Share issue costs - (7,329) Balance, March 31, 2014 11,641,667 1,658,585 Issued under private placement (x) 3,430,756 2,616,062 Issued on conversion and settlement of debt (xi), (xii), (xiii) 321,748 239,746 Issued on the exercise of options (xiv) 416,667 335,060 Share issue costs (x) - (11,609) Balance December 31, 2014 15,810,838 4,837,844 (i) The opening balance consists of 7,750,000 2 1,000,000 250,000 1,250,000 3 (ii) In May, 2012, the Company issued through a private placement, 291,667 0.59 0.60 170,815 (iii) In May, 2012, 200,000 117,192 (iv) In June, 2012, the Company issued through a private placement, 895,834 0.58 0.60 519,420 (v) In August, 2012, 125,000 250,000 (vi) In September, 2012, the Company issued through a private placement, 437,500 0.59 0.60 256,016 (vii) In December, 2012, the Company issued through a private placement, 383,333 0.61 0.60 232,546 (viii) In March 2013, the Company issued through a private placement, 516,666 0.60 0.60 308,183 58,846 (ix) In June, 2013, the Company issued through a private placement, 166,667 0.58 0.60 96,320 (x) In April, 2014, the Company completed a private placement issuing 3,182,978 0.82 0.90 2,616,062 2,864,680 247,778 11,609 (xi) In May 2014, the Company issued 105,555 87,638 95,000 (xii) In May 2014, the Company issued 33,333 27,585 30,000 (xiii) In June, 2014, the Company issued 182,860 124,523 131,659 20 0.68 0.90 (xiv) In June 2014, the Company issued 416,667 228,875 250,000 106,185

STOCK OPTIONS (Tables)

STOCK OPTIONS (Tables)	6 Months Ended	9 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	These options granted and revalued during the period ended June 30, 2015 were valued using the Black-Scholes option pricing model with the following key assumptions: February 17, July 1, June 20, April 11, Expected life in years 5 4.35 6.32 4.14 Risk free rate 1.59 % 1.59 % 1.59 % 1.59 % Dividend yield 0 % 0 % 0 % 0 % Forfeiture rate 0 % 0 % 0 % 0 % Expected volatility 114 % 114 % 114 % 114 %	These options were valued using the Black-Scholes option pricing model with the following key assumptions: Expected life 7 years Risk free rate 1.59 % Dividend yield 0 % Forfeiture rate 0 % Volatility (based upon similar public companies) 114 %
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	A summary of the Company’s outstanding options is as follows: Number of Options Weighted-Average Outstanding, December 31, 2013 1,310,665 0.19 Exercised (1,310,665) 0.19 Issued 3,894,252 0.22 Cancelled (125,824) 0.17 Outstanding, December 31, 2014 3,768,428 0.22 Cancelled as a result of Merger (3,768,428) 0.22 Re-issued as part of Merger 3,768,428 0.22 Issued 314,560 0.23 Cancelled (157,281) 0.23 Outstanding, June 30, 2015 3,925,707 0.22	A summary of the Company’s outstanding and exercisable options is as follows: Number of Weighted Average Weighted Average options Exercise Price Remaining Contract Life # $ (Years) Outstanding, March 31, 2012 and 2013 - - - Granted during the year 416,667 0.52 - Outstanding March 31, 2014 416,667 0.52 0.20 Exercised during the period (416,667) 0.52 - Granted during the period 1,238,000 0.73 7 Cancelled during the period (40,000) 0.52 - Outstanding, December 31, 2014 1,198,000 0.74 6.72
Share-based Compensation, Performance Shares Award Outstanding Activity [Table Text Block]	The following is a summary of stock options outstanding as of June 30, 2015: Exercise Price ($) Number of Options Expiry Date Number of 0.165 531,606 April 1, 2021 354,404 0.23 159,377 June 20, 2021 123,727 0.23 2,972,592 July 1, 2021 2,972,592 0.23 262,132 February 17, 2022 104,857 3,925,707 3,555,580

WARRANTS (Tables)

WARRANTS (Tables)	6 Months Ended
	Jun. 30, 2015
Warrants and Rights Note Disclosure [Abstract]
Schedule Of Share Based Compensation Stock Purchase Warrants Activity [Table Text Block]	The following is a continuity schedule of the Company's common share purchase warrants: Number of Weighted-Average Outstanding and exercisable, December 31, 2014 and 2013 - - Issued 18,049,075 1.35 Outstanding and exercisable, June 30, 2015 18,049,075 1.35
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	The following is a summary of common share purchase warrants outstanding as of June 30, 2015: Exercise Number of Expiry Date 1.40 Note 8(vi) 7,735,750 February 26, 2019 0.80 Note 8(vi) 773,575 February 26, 2019 1.40 Note 8(viii) 1,212,500 March 27, 2019 0.80 Note 8(viii) 121,250 March 27, 2019 1.40 Note 8(ix) 891,250 March 31, 2019 0.80 Note 8(ix) 89,125 March 31, 2019 1.40 Note 8(x) 3,115,000 April 21, 2019 0.80 Note 8(x) 311,500 April 21, 2019 1.40 Note 8(xi) 1,418,750 May 27, 2019 0.80 Note 8(xi) 141,875 May 27, 2019 1.40 Note 8(xii) 2,035,000 June 30, 2019 0.80 Note 8(xii) 203,500 June 30, 2019 18,049,075

INCOME TAXES (Tables)

INCOME TAXES (Tables)	9 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	9 month periods ended Years ended December 31, 2014 March 31, 2014 March 31, 2013 $ $ $ Components of net loss before income taxes consists of the following: U.S. - - - Canada (2,464,747) (1,451,769) (937,059) (2,464,747) (1,451,769) (937,059) 2014 2014 2013 $ $ $ Net loss before recovery of income taxes (2,464,747) (1,451,769) (937,059) Statutory rate 26.50 % 26.50 % 26.50 % Expected income tax recovery (653,158) (384,719) (248,321) Other basis adjustment (29,109) (6,966) (8,576) Non-deductible expenses 193,305 148,936 (38,493) Change in valuation allowance 488,962 242,749 295,390 Recovery of income taxes - - -
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	The components of deferred taxes are as follows: 2014 2014 2013 $ $ $ Deferred tax assets Current - 403 - Valuation allowance - (403) - - - - Long-term $ $ $ Unrealized tax credits - 19,591 19,721 Property and equipment 36,940 23,985 - Share issue costs 7,137 6,461 7,228 SR&ED pool 162,350 - - Other 18,621 - - Net operating losses 812,522 529,889 310,228 Valuation allowance (1,037,570) (579,926) (337,177) - - -

NATURE OF OPERATIONS (Details T

NATURE OF OPERATIONS (Details Textual)	1 Months Ended	3 Months Ended		6 Months Ended		9 Months Ended		12 Months Ended
	Feb. 26, 2015shares	Jun. 30, 2015USD ($)shares	Jun. 30, 2014USD ($)	Jun. 30, 2015USD ($)shares	Jun. 30, 2014USD ($)	Dec. 31, 2014USD ($)shares	Dec. 31, 2013USD ($)	Mar. 31, 2014USD ($)	Mar. 31, 2013USD ($)	Mar. 31, 2012USD ($)
Working Capital Surplus (Deficit)		$ 9,204,368		$ 9,204,368		$ (128,361)		$ (781,378)
Stockholders' Equity Attributable to Parent		9,318,912		9,318,912		(50,439)	$ (710,982)	(774,626)	$ 471,822	$ (183,721)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent		$ (2,418,910)	$ (630,689)	$ (3,641,241)	$ (790,197)	$ (2,489,137)	$ (1,429,108)	$ (1,433,485)	$ (914,046)
Stockholders' Equity, Reverse Stock Split				1-for-0.831105
Common Stock, Shares Authorized | shares		150,000,000		150,000,000		200,000,000
Share Exchange Agreement [Member]
Stock Issued During Period, Shares, New Issues | shares	50,000,000
Debt Instrument, Convertible, Conversion Ratio	3.14
Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage	100.00%

SIGNIFICANT ACCOUNTING POLICI31

SIGNIFICANT ACCOUNTING POLICIES (Details Textual)	9 Months Ended
	Dec. 31, 2014
Computers and Electronics [Member]
Significant Accounting Policies [Line Items]
Percentage Of Depreciated Per Annum	50.00%
Furniture and Fixtures [Member]
Significant Accounting Policies [Line Items]
Percentage Of Depreciated Per Annum	20.00%
Tools, Dies and Molds [Member]
Significant Accounting Policies [Line Items]
Percentage Of Depreciated Per Annum	20.00%

PREPAID EXPENSES AND OTHER RE32

PREPAID EXPENSES AND OTHER RECEIVABLES (Details) - USD ($)		Jun. 30, 2015	Dec. 31, 2014	Mar. 31, 2014
Prepaid Expense And Other Receivables [Line Items]
Prepaid expenses and sundry receivables		$ 57,603	$ 18,172	$ 11,700
Prepaid insurance		68,671	40,630	0
IRAP Grant receivable (i)	[1]		0	63,300
Investment tax credit receivable (ii)	[2]		0	408,506
Sales taxes receivable	[3]	38,079	22,328	22,281
Prepaid Expense and Other Assets		$ 164,353	$ 81,130	$ 505,787
[1]	Industrial Research Assistance Program ("IRAP") grant receivable is the value of claim receivable from the Government of Canada for recovery of eligible expenditures. The grant proceeds are recognized as 'Other Income' in the statements of operations and comprehensive loss, when received.
[2]	Investment tax credit receivable is the estimated Scientific Research and Experimental Development ("SR&ED") claim receivable from the Government of Canada for input tax credits that are granted on qualifying SR&ED expenditures. The recovery, which was received in November 2014, is recognized as 'Other Income' in the statements of operations and comprehensive loss.
[3]	Sales tax receivable represents net harmonized sales taxes (HST) input tax credits receivable from the Government of Canada.

LOAN RECEIVABLE (Details Textua

LOAN RECEIVABLE (Details Textual)	6 Months Ended
	Jun. 30, 2015USD ($)
Accounts, Notes, Loans and Financing Receivable [Line Items]
Long-term Debt, Maturities, Repayment Terms	repayable in 10 months
Loans and Leases Receivable, Related Parties	$ 150,000
Debt Instrument, Interest Rate, Stated Percentage	6.00%
Interest Payable, Current	$ 1,130

EQUIPMENT (Details)

EQUIPMENT (Details) - USD ($)	Jun. 30, 2015	Dec. 31, 2014	Mar. 31, 2014
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 178,508	$ 114,472	$ 11,194
Accumulated Depreciation	63,964	36,550	4,442
Property, Plant and Equipment, Net	114,544	77,922	6,752
Computers and electronics [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	141,686	77,650	0
Accumulated Depreciation	53,865	27,438	0
Property, Plant and Equipment, Net	87,821	50,212	0
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	24,909	24,909	11,194
Accumulated Depreciation	8,496	7,325	4,442
Property, Plant and Equipment, Net	16,413	17,584	6,752
Tools and Parts [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	11,913	11,913	0
Accumulated Depreciation	1,603	1,787	0
Property, Plant and Equipment, Net	$ 10,310	$ 10,126	$ 0

EQUIPMENT (Details Textual)

EQUIPMENT (Details Textual) - USD ($)	3 Months Ended		6 Months Ended		9 Months Ended		12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014	Dec. 31, 2013	Mar. 31, 2014	Mar. 31, 2013
Property, Plant and Equipment [Line Items]
Depreciation	$ 17,002	$ 11,492	$ 27,414	$ 22,691	$ 34,036	$ 1,349	$ 1,772	$ 2,330
Property, Plant and Equipment, Additions					$ 109,316	$ 4,557		$ 8,695

CONVERTIBLE SECURED PROMISSOR36

CONVERTIBLE SECURED PROMISSORY NOTE (Details Textual)	May. 09, 2014$ / shares	Dec. 08, 2011CAD	Feb. 28, 2014	Feb. 28, 2012CAD	Jun. 30, 2015CAD	Dec. 31, 2014USD ($)	Dec. 31, 2013USD ($)	Mar. 31, 2014USD ($)	Mar. 31, 2013USD ($)	May. 09, 2014CAD / shares
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage					6.00%
Debt Instrument, Maturity Date					Feb. 28, 2014
Debt Instrument, Basis Spread on Variable Rate					1.00%	1.00%
Interest Expense, Debt						$ 0	$ 0	$ 19,223	$ 0
Convertible Notes Payable [Member]
Debt Instrument [Line Items]
Proceeds from Issuance of Debt | CAD		CAD 61,500
Proceeds From Issuance Of Additional Debt | CAD				CAD 60,000
Debt Instrument, Face Amount				CAD 121,500				$ 105,262
Debt Instrument, Interest Rate, Stated Percentage								10.00%
Debt Instrument, Description			convert the principal plus accrued interest at a discount of 20% to the share price in the event of a qualifying financing					convert the principal plus accrued interest at a discount of 20% to the share price in the event of a qualifying financing
Debt Instrument, Maturity Date								Feb. 28, 2014
Debt Instrument, Convertible, Beneficial Conversion Feature					CAD 27,677			$ 27,677
Debt Instrument, Basis Spread on Variable Rate			0.00%	1.00%
Debt Instrument, Unamortized Discount								16,238
Interest Expense, Debt						$ 27,677	$ 55,647	$ 3,939	$ 7,282
Fair Value Inputs, Discount Rate	20.00%
Debt Instrument, Convertible, Conversion Price | (per share)	$ 0.81									CAD 0.90

LOANS PAYABLE (Details)

LOANS PAYABLE (Details) - USD ($)		Dec. 31, 2014	Mar. 31, 2014
Debt Conversion [Line Items]
Loans Payable, Current		$ 0	$ 772,146
Lieberman Family Trust [Member]
Debt Conversion [Line Items]
Loans Payable, Current	[1]	0	27,141
Gaston-Dreyfus Remi [Member]
Debt Conversion [Line Items]
Loans Payable, Current	[2]	0	454,729
Parvez Patel Huda [Member]
Debt Conversion [Line Items]
Loans Payable, Current	[2]	0	100,766
Pope & Co [Member]
Debt Conversion [Line Items]
Loans Payable, Current	[3]	$ 0	$ 189,510
[1]	During the nine month period ended December 31, 2014, the loan from Lieberman Family Trust and accrued interest thereon was settled in exchange for 33,333 common shares (Note 8(xii)).
[2]	During the nine month period ended December 31, 2014, the Company repaid the loan of $452,350 ($500,000 CAD) from Gaston-Dreyfus Remi plus accrued interest and the loan of $99,517 ($110,000 CAD) plus accrued interest from Parvez Patel/Huda (both unrelated parties).
[3]	During the nine month period ended December 31, 2014, the Company repaid loans for $180,940 ($200,000 CAD) plus accrued interest of $12,138 ($13,417 CAD) owing to investors introduced by Pope and Co. As part of this transaction the Company will issue to these lenders 349,522 warrants exercisable into common shares of BLC (Note 13(c)) at an exercise price of $0.23 per share for a period of up to two years.

LOANS PAYABLE (Details Textual)

LOANS PAYABLE (Details Textual)	6 Months Ended	9 Months Ended		12 Months Ended
	Jun. 30, 2015	Dec. 31, 2014USD ($)$ / sharesshares	Dec. 31, 2014CADshares	Mar. 31, 2014USD ($)$ / sharesshares	Mar. 31, 2014CADshares	Mar. 31, 2014CAD
Loan Payable [Line Items]
Debt Conversion, Converted Instrument, Shares Issued | shares		33,333	33,333
Debt Instrument, Interest Rate, Stated Percentage	6.00%
Stock To Be Issued Upon Conversion of Stock Option | shares				416,666	416,666
Fair Value of Stock Option Issued				$ 106,185
Relative Fair Value Of Options Issued And Contributed Capital From Shareholders				$ 98,046
Share Price | $ / shares				$ 0.58
Debt Conversion, Original Debt, Amount				$ 58,000	CAD 60,000
Accretion of Discount				98,046
Debt Instrument, Maturity Date	Feb. 28, 2014
Common Stock [Member]
Loan Payable [Line Items]
Debt Instrument, Fair Value Disclosure				$ 34,565
Employee Stock Option [Member]
Loan Payable [Line Items]
Stock Issued During Period, Shares, Issued for Services | shares				100,000	100,000
Debt Instrument, Fair Value Disclosure				$ 63,481
Loans Payable [Member]
Loan Payable [Line Items]
Debt Instrument, Fair Value Disclosure				$ 143,139
Lieberman Family Trust [Member]
Loan Payable [Line Items]
Debt Instrument, Interest Rate, Stated Percentage				10.00%		10.00%
Debt Instrument, Payment Terms				90 days	90 days
Minimum Capital to be Raised for Redemption of Loans				$ 2,711,700		CAD 3,000,000
Gaston-Dreyfus Remi [Member]
Loan Payable [Line Items]
Debt Instrument, Periodic Payment		$ 452,350	CAD 500,000
Debt Instrument, Interest Rate, Stated Percentage				6.00%		6.00%
Parvez Patel Huda [Member]
Loan Payable [Line Items]
Debt Instrument, Periodic Payment		99,517	110,000
Debt Instrument, Interest Rate, Stated Percentage				2.00%		2.00%
Minimum Capital to be Raised for Redemption of Loans				$ 5,694,570		CAD 6,300,000
Pope And Co [Member]
Loan Payable [Line Items]
Debt Instrument, Periodic Payment, Principal		180,940	200,000
Debt Instrument, Periodic Payment, Interest		$ 12,138	CAD 13,417
Debt Instrument, Interest Rate, Stated Percentage				10.00%		10.00%
Debt Instrument, Payment Terms				90 days	90 days
Minimum Capital to be Raised for Redemption of Loans				$ 2,711,700		CAD 3,000,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares		349,522
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares		$ 0.23
Secured Debt [Member]
Loan Payable [Line Items]
Secured Debt				$ 241,185		CAD 250,000
Debt Instrument, Interest Rate, Stated Percentage				10.00%		10.00%
Debt Instrument, Maturity Date				Jun. 10, 2014	Jun. 10, 2014

RELATED PARTY TRANSACTIONS AN39

RELATED PARTY TRANSACTIONS AND BALANCES (Details Textual)	6 Months Ended		9 Months Ended
	Jun. 30, 2015USD ($)	Jun. 30, 2015CAD	Dec. 31, 2014USD ($)shares	Dec. 31, 2014CADshares	Dec. 31, 2013USD ($)	Mar. 31, 2014USD ($)
Related Party Transaction [Line Items]
Due from Related Parties	$ 42,151		$ 44,986			$ (149,899)
Debt Instrument, Basis Spread on Variable Rate	1.00%	1.00%	1.00%	1.00%
Repayments of Related Party Debt	$ 37,837	CAD 44,000	$ 37,837	CAD 44,000
Accounts Payable, Related Parties	42,151
Director [Member]
Related Party Transaction [Line Items]
Related Party Transaction, Amounts of Transaction	85,947		$ 85,947	CAD 95,000	$ 0
Stock Issued During Period, Shares, Issued for Services | shares			105,555	105,555
Accounts Payable, Related Parties			$ 0			48,673
Chief Operating Officer [Member]
Related Party Transaction [Line Items]
Accounts Payable, Related Parties	22,115
Chief Executive Officer [Member]
Related Party Transaction [Line Items]
Accounts Payable, Related Parties	6,567		4,220			16,235
Chief Technology Officer [Member]
Related Party Transaction [Line Items]
Accounts Payable, Related Parties	7,448		$ 5,930			$ 0
Chief Financial Officer [Member]
Related Party Transaction [Line Items]
Accounts Payable, Related Parties	$ 8,893

SHARE CAPITAL (Details)

SHARE CAPITAL (Details) - USD ($)		6 Months Ended			9 Months Ended		12 Months Ended
		Jun. 30, 2015		Jun. 30, 2014	Dec. 31, 2014		Dec. 31, 2014		Mar. 31, 2014	Mar. 31, 2013
Balance		$ (50,439)		$ (710,982)	$ (774,626)		$ (710,982)		$ 471,822	$ (183,721)
Stock Issued During Period, Value, New Issues				2,616,062	$ 2,616,062				96,320	1,486,980
Shares issued for services										117,192
Shares issued on conversion and settlement of debt (in shares)					33,333
Shares issued on the exercise of options				$ 228,875	$ 228,875
Shares issued as Acquisition Transaction consideration		0
Balance		$ 9,318,912			$ (50,439)		$ (50,439)		$ (774,626)	$ 471,822
Common Stock [Member]
Balance (in shares)		49,737,096		36,621,885	11,641,667		36,621,885		11,475,000	9,000,000	[1]
Balance		$ 4,837,844		$ 36,622	$ 1,658,585		$ 36,622		$ 1,569,594	$ 5	[1]
Stock Issued During Period, Shares, New Issues (in shares)				10,792,335	3,430,756				166,667	2,525,000
Stock Issued During Period, Value, New Issues				$ 10,792	$ 2,616,062				$ 96,320	$ 1,486,980
Financial Services Costs					$ (11,609)	[2]			$ (7,329)	$ (34,583)
Stock Repurchased and Retired During Period, Shares (in shares)	[3]									(250,000)
Stock Repurchased and Retired During Period, Value	[3]									$ 0
Shares issued for services (in shares)	[4]									200,000
Shares issued for services	[4]									$ 117,192
Shares issued on the exercise of options (in shares)				1,310,734	416,667	[5]
Shares issued on the exercise of options				$ 1,311	$ 335,060	[5]
Shares issued as Acquisition Transaction consideration (in shares)		6,000,063
Shares issued as Acquisition Transaction consideration		$ 6,000
Balance (in shares)		72,408,313			49,737,096		49,737,096		11,641,667	11,475,000
Balance		$ 72,408			$ 4,837,844		$ 4,837,844		$ 1,658,585	$ 1,569,594
Common Stock [Member] | Debt [Member]
Stock Issued During Period, Shares, New Issues (in shares)	[6],[7],[8]				321,748
Stock Issued During Period, Value, New Issues	[6],[7],[8]				$ 239,746
Common Stock [Member] | Private Placement [Member]
Stock Issued During Period, Shares, New Issues (in shares)	[9]									291,667
Stock Issued During Period, Value, New Issues	[9]									$ 170,815
Common Stock [Member] | Private Placement One [Member]
Stock Issued During Period, Shares, New Issues (in shares)	[10]									895,834
Stock Issued During Period, Value, New Issues	[10]									$ 519,420
Common Stock [Member] | Private Placement Two [Member]
Stock Issued During Period, Shares, New Issues (in shares)	[11]									437,500
Stock Issued During Period, Value, New Issues	[11]									$ 256,016
Common Stock [Member] | Private Placement Three [Member]
Stock Issued During Period, Shares, New Issues (in shares)	[12]									383,333
Stock Issued During Period, Value, New Issues	[12]									$ 232,546
Common Stock [Member] | Private Placement Four [Member]
Stock Issued During Period, Shares, New Issues (in shares)	[13]									516,666
Stock Issued During Period, Value, New Issues	[13]									$ 308,183
Common Stock [Member] | Private Placement Five [Member]
Stock Issued During Period, Shares, New Issues (in shares)	[14]								166,667
Stock Issued During Period, Value, New Issues	[14]								$ 96,320
Common Stock [Member] | Private Placement Six [Member]
Stock Issued During Period, Shares, New Issues (in shares)	[2]				3,430,756
Stock Issued During Period, Value, New Issues	[2]				$ 2,616,062
Exchangable Shares [Member]
Balance (in shares)		49,737,096		36,621,885			36,621,885
Balance		$ 49,737		$ 36,622			$ 36,622
Shares issued for services (in shares)		262,904	[15]				0
Shares issued for services		$ 263	[15]				$ 0
Shares issued under private placement (in shares)		0					10,792,335	[16]
Shares issued under private placement		$ 0					$ 10,792	[16]
Shares issued on conversion and settlement of debt (in shares)		0					1,012,142	[17],[18]
Shares issued on conversion and settlement of debt		$ 0					$ 1,012	[17],[18]
Shares issued on the exercise of options (in shares)		0					1,310,734	[19]
Shares issued on the exercise of options		$ 0					$ 1,311	[19]
Balance (in shares)		50,000,000			49,737,096		49,737,096
Balance		$ 50,000			$ 49,737		$ 49,737
Common Shares [Member]
Balance (in shares)		0		0			0
Balance		$ 0		$ 0			$ 0
Shares issued under private placement (in shares)		16,408,250	[15],[20]				0
Shares issued under private placement		$ 16,408	[15],[20]				$ 0
Shares issued as Acquisition Transaction consideration (in shares)		6,000,063	[21]				0
Shares issued as Acquisition Transaction consideration		$ 6,000	[21]				$ 0
Balance (in shares)		22,408,313			0		0
Balance		$ 22,408			$ 0		$ 0
[1]	The opening balance consists of 7,750,000 common shares issued to its two founders for a consideration of $2, 1,000,000 commons shares issued to two directors and 250,000 common shares to a consultant for a total of 1,250,000 common shares for consideration of $3.
[2]	In April, 2014, the Company completed a private placement issuing 3,182,978 common shares at a price of $0.82 ($0.90 CAD) per share for gross proceeds of $2,616,062 ($2,864,680 CAD). A former director of the Company assisted in securing a significant portion of this financing. As a result the Company issued 247,778 common shares as a finder’s fee to this director. The Company also incurred $11,609 in share issue costs related to the transaction.
[3]	In August, 2012, 125,000 common shares each issued to the two founders on March 24, 2011, for a total of 250,000 common shares were cancelled.
[4]	In May, 2012, 200,000 common shares valued at $117,192 were issued for settlement of accounts payable relating to services performed in the prior year, which is included in general and administrative expenses for the year ended March 31, 2013.
[5]	In June 2014, the Company issued 416,667 common shares for the exercise of stock options. The Company received cash of $228,875 ($250,000 CAD). The value of the options, $106,185, was transferred from contributed surplus to share capital on exercise.
[6]	In June, 2014, the Company issued 182,860 common shares on conversion of the convertible secured promissory note (Note 5). The note plus accrued interest totaled $124,523 ($131,659 CAD) and was converted at a 20% discount to the $0.68 ($0.90 CAD) April 2014 private placement.
[7]	In May 2014, the Company issued 105,555 common shares to a director of the Company in exchange for the settlement of $87,638 ($95,000 CAD) of unsecured debt.
[8]	In May 2014, the Company issued 33,333 common shares to the Libermann Family Trust in exchange for the settlement of $27,585 ($30,000 CAD) of unsecured debt.
[9]	In May, 2012, the Company issued through a private placement, 291,667 common shares at a price of $0.59 (0.60 CAD) per share for aggregate gross proceeds of $170,815.
[10]	In June, 2012, the Company issued through a private placement, 895,834 common shares at a price of $0.58 (0.60 CAD) per share for aggregate gross proceeds of $519,420.
[11]	In September, 2012, the Company issued through a private placement, 437,500 common shares at a price of $0.59 (0.60 CAD) per share for aggregate gross proceeds of $256,016.
[12]	In December, 2012, the Company issued through a private placement, 383,333 common shares at a price of $0.61 (0.60 CAD) per share for aggregate gross proceeds of $232,546.
[13]	In March 2013, the Company issued through a private placement, 516,666 common shares at a price of $0.60 (0.60 CAD) per share for aggregate gross proceeds of $308,183. $58,846 of the proceeds were not received as at March 31, 2013 and accordingly are presented as subscriptions receivable on the balance sheet.
[14]	In June, 2013, the Company issued through a private placement, 166,667 common shares at a price of $0.58 ($0.60 CAD) per share for aggregate gross proceeds of $96,320.
[15]	On February 25, 2015, 262,904 common shares were issued to two former lenders connected with a $241,185 loan received and repaid during fiscal 2013. The common shares were valued at $210,323 based on the value of the concurrent private placement (Note 8(vi)), and recorded in stock-based compensation on the unaudited condensed consolidated interim statement of operations and comprehensive loss. As part of the consideration for the initial loan the CTO and COO had transferred 314,560 common shares to the lenders. For contributing the common shares to the lenders the Company intends to reimburse the CTO and COO 320,000 common shares; however, these shares have not yet been issued.
[16]	In April, 2014, the Company completed a private placement issuing 10,792,335 common shares at a price of $0.24 per share for gross proceeds of $2,590,160. A former director of the Company assisted in securing a significant portion of this financing. The Company incurred $11,609 in share issue costs related to the transaction.
[17]	In June, 2014, the Company issued 575,234 common shares on conversion of the convertible secured promissory note (Note 6). The note plus accrued interest totaled $124,523 and was converted at a 20% discount to the April 2014 private placement.
[18]	In May 2014, the Company issued 436,908 common shares in exchange for the settlement of $115,223 of unsecured debt.
[19]	In June 2014, the Company issued 1,310,734 common shares for the exercise of stock options. The Company received cash of $228,875.
[20]	On June 30, 2015, the Company issued 2,035,000 Units for gross proceeds of $1,628,000 to accredited investors in a sixth and final closing (the “Sixth Closing”). Each Unit consisted of one common share of the Company, and a warrant to purchase one common share of the Company at an exercise price of $1.40 per share exercisable for 4 years. The Company incurred share issue costs before legal and other costs related to the Sixth Closing of $211,656 and issued 203,500 broker warrants exercisable at $0.80 for a period of 4 years.
[21]	Immediately following the Merger and the First Closing, 6,000,063 common shares were held by existing Drywave stockholders, 7,735,750 were held by the investors in the Offering and Bionik Canada shareholders held an equivalent of 50,000,000 shares of our common shares through their ownership of 100% of the Exchangeable Shares which are held in 1 Special Preferred Share. The Special Preferred Share has the right to 50,000,000 common shares and to vote alongside the common shares of the Company as a single class.

SHARE CAPITAL (Details Textual)

SHARE CAPITAL (Details Textual)		1 Months Ended		3 Months Ended			6 Months Ended		9 Months Ended					12 Months Ended
		Jun. 30, 2014USD ($)shares	May. 30, 2014USD ($)shares	Jun. 30, 2015USD ($)$ / sharesshares	Mar. 31, 2015USD ($)shares	Jun. 30, 2014USD ($)	Jun. 30, 2015USD ($)$ / shares$ / Unitshares	Jun. 30, 2014USD ($)shares	Dec. 31, 2014USD ($)$ / sharesshares		Dec. 31, 2014CADshares		Dec. 31, 2013USD ($)shares	Mar. 31, 2014USD ($)$ / sharesshares	Mar. 31, 2013USD ($)$ / sharesshares	Dec. 31, 2014CAD / shares	Mar. 31, 2013CAD / shares	Mar. 31, 2012USD ($)shares
Debt Conversion, Converted Instrument, Shares Issued | shares									33,333		33,333
Stock Issued During Period, Value, Stock Options Exercised								$ 228,875	$ 228,875
Stock Issued During Period, Value, Issued for Services															$ 117,192
Share-based Compensation				$ 1,297,558		$ 19,748	$ 1,669,195	90,286	112,573				$ 0	$ 0	0
Class of Warrant or Right, Outstanding | shares				18,049,075			18,049,075
Stockholders' Equity Attributable to Parent				$ 9,318,912			$ 9,318,912		(50,439)				(710,982)	(774,626)	471,822			$ (183,721)
Stock Issued During Period, Value, New Issues								2,616,062	2,616,062					96,320	1,486,980
Proceeds from Stock Options Exercised							$ 0	$ 228,875	$ 228,875				$ 0	$ 0	$ 0
Unsecured Debt [Member]
Debt Conversion, Converted Instrument, Shares Issued | shares			436,908
Debt Conversion, Converted Instrument, Amount			$ 115,223
Common Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period | shares								1,310,734	416,667	[1]	416,667	[1]
Stock Issued During Period, Value, Stock Options Exercised								$ 1,311	$ 335,060	[1]
Stock Issued During Period, Shares, Issued for Services | shares	[2]														200,000
Stock Issued During Period, Value, Issued for Services	[2]														$ 117,192
Stock Issued During Period, Shares, Acquisitions | shares							6,000,063
Shares, Outstanding | shares				72,408,313			72,408,313		49,737,096				36,621,885	11,641,667	11,475,000			9,000,000	[3]
Stockholders' Equity Attributable to Parent				$ 72,408			$ 72,408		$ 4,837,844				$ 36,622	$ 1,658,585	$ 1,569,594			$ 5	[3]
Stock Issued During Period, Shares, New Issues | shares								10,792,335	3,430,756		3,430,756			166,667	2,525,000
Stock Issued During Period, Value, New Issues								$ 10,792	$ 2,616,062					$ 96,320	$ 1,486,980
Stock Repurchased and Retired During Period, Shares | shares	[4]														250,000
Proceeds from Stock Options Exercised									228,875		CAD 250,000
Stock Issued During Period, Value, Employee Stock Ownership Plan									$ 106,185
Common Stock [Member] | Debt One [Member]
Stock Issued During Period, Shares, New Issues | shares									105,555		105,555
Stock Issued During Period, Value, New Issues									$ 87,638		CAD 95,000
Common Stock [Member] | Libermann Family Trust [Member]
Stock Issued During Period, Shares, New Issues | shares									33,333		33,333
Stock Issued During Period, Value, New Issues									$ 27,585		CAD 30,000
Principal Owner [Member] | Common Stock [Member]
Shares, Outstanding | shares															7,750,000
Stockholders' Equity Attributable to Parent															$ 2
Director [Member]
Stock Issued During Period, Shares, Issued for Services | shares									105,555		105,555
Director [Member] | Common Stock [Member]
Shares, Outstanding | shares															250,000
Consultant [Member] | Common Stock [Member]
Shares, Outstanding | shares															1,250,000
Director and Consultant [Member] | Common Stock [Member]
Stockholders' Equity Attributable to Parent															$ 3
Two Founders [Member] | Common Stock [Member]
Stock Repurchased and Retired During Period, Shares | shares															125,000
Private Placement [Member] | Common Stock [Member]
Shares Issued, Price Per Share | (per share)															$ 0.59		CAD 0.60
Proceeds from Issuance of Private Placement															$ 170,815
Stock Issued During Period, Shares, New Issues | shares	[5]														291,667
Stock Issued During Period, Value, New Issues	[5]														$ 170,815
Exchangable Shares [Member]
Stock Issued During Period, Shares, Other | shares									10,792,335		10,792,335
Shares Issued, Price Per Share | $ / shares									$ 0.24
Proceeds from Issuance of Private Placement									$ 2,590,160
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period | shares		1,310,734
Stock Issued During Period, Value, Stock Options Exercised		$ 228,875
Stock Transferred To Lenders | shares					314,560
Stock Reimbursed To Officers | shares					320,000
Stock Issued During Period, Shares, Issued for Services | shares					262,904
Stock Issued During Period, Value, Issued for Services					$ 241,185
Share-based Compensation					$ 210,323
Payments of Stock Issuance Costs									$ 11,609
First Closing [Member]
Stock Units Issued During Period | shares							7,735,750
Proceeds From Issuance of Stock Units							$ 6,188,600
Stock Units Issued During Period, Purchase Price Per Unit | $ / Unit							0.80
Stock Units Description							Each Unit consists of one common share of the Company, and a warrant to purchase one common share of the Company at an exercise price of $1.40 per share exercisable for 4 years.
Warrants Exercisable Period							4 years
Bridge Loan				$ 500,000			$ 500,000
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares				$ 0.80			$ 0.80
Payments of Stock Issuance Costs							$ 848,822
Class of Warrant or Right, Outstanding | shares				773,575			773,575
Stock Issued During Period, Shares, Acquisitions | shares							50,000,000
Business Acquisition, Percentage of Voting Interests Acquired				100.00%			100.00%
First Closing [Member] | Investor [Member]
Stock Issued During Period, Shares, Acquisitions | shares							7,735,750
First Closing [Member] | Drywave Stockholders [Member]
Stock Issued During Period, Shares, Acquisitions | shares							6,000,063
Second Closing [Member]
Stock Units Issued During Period | shares							1,212,500
Proceeds From Issuance of Stock Units							$ 970,000
Stock Units Description							Each Unit consisted of one common share of the Company, and a warrant to purchase one common share of the Company at an exercise price of $1.40 per share exercisable for 4 years.
Warrants Exercisable Period							4 years
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares				$ 0.80			$ 0.80
Payments of Stock Issuance Costs							$ 141,100
Class of Warrant or Right, Outstanding | shares				121,250			121,250
Third Closing [Member]
Stock Units Issued During Period | shares							891,250
Proceeds From Issuance of Stock Units							$ 713,000
Stock Units Description							Each Unit consisted of one common share of the Company, and a warrant to purchase one common share of the Company at an exercise price of $1.40 per share exercisable for 4 years.
Warrants Exercisable Period							4 years
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares				$ 0.80			$ 0.80
Payments of Stock Issuance Costs							$ 92,690
Class of Warrant or Right, Outstanding | shares				89,125			89,125
Convertible Secured Promissory Note [Member]
Debt Conversion, Converted Instrument, Shares Issued | shares		575,234
Debt Conversion, Converted Instrument, Amount		$ 124,523
Debt Conversion, Converted Instrument, Rate		20.00%
Private Placement One [Member] | Common Stock [Member]
Shares Issued, Price Per Share | (per share)															$ 0.58		0.60
Proceeds from Issuance of Private Placement															$ 519,420
Stock Issued During Period, Shares, New Issues | shares	[6]														895,834
Stock Issued During Period, Value, New Issues	[6]														$ 519,420
Private Placement Two [Member] | Common Stock [Member]
Shares Issued, Price Per Share | (per share)															$ 0.59		0.60
Proceeds from Issuance of Private Placement															$ 256,016
Stock Issued During Period, Shares, New Issues | shares	[7]														437,500
Stock Issued During Period, Value, New Issues	[7]														$ 256,016
Private Placement Three [Member] | Common Stock [Member]
Shares Issued, Price Per Share | (per share)															$ 0.61		0.60
Proceeds from Issuance of Private Placement															$ 232,546
Stock Issued During Period, Shares, New Issues | shares	[8]														383,333
Stock Issued During Period, Value, New Issues	[8]														$ 232,546
Private Placement Four [Member] | Common Stock [Member]
Shares Issued, Price Per Share | (per share)															$ 0.60		0.60
Proceeds from Issuance of Private Placement															$ 308,183
Stock Issued During Period, Shares, New Issues | shares	[9]														516,666
Stock Issued During Period, Value, New Issues	[9]														$ 308,183
Due From Issuance Of Private Placement															$ 58,846
Private Placement Five [Member] | Common Stock [Member]
Shares Issued, Price Per Share | (per share)														$ 0.58			CAD 0.60
Proceeds from Issuance of Private Placement														$ 96,320
Stock Issued During Period, Shares, New Issues | shares	[10]													166,667
Stock Issued During Period, Value, New Issues	[10]													$ 96,320
Private Placement Six [Member] | Common Stock [Member]
Shares Issued, Price Per Share | (per share)									$ 0.82							CAD 0.90
Proceeds from Issuance of Private Placement									$ 2,616,062		CAD 2,864,680
Payments of Stock Issuance Costs									$ 11,609
Stock Issued During Period, Shares, New Issues | shares	[11]								3,430,756		3,430,756
Stock Issued During Period, Value, New Issues	[11]								$ 2,616,062
Stock Issued During Period Value New Issues To Directors									$ 247,778
Private Placement Seven [Member] | Common Stock [Member]
Shares Issued, Price Per Share | (per share)									$ 0.68							CAD 0.90
Stock Issued During Period, Shares, Conversion of Units | shares									182,860		182,860
Debt Instrument, Increase, Accrued Interest									$ 124,523		CAD 131,659
Debt Instrument, Interest Rate, Effective Percentage									20.00%
Fifth Closing [Member]
Stock Units Issued During Period | shares							1,418,750
Proceeds From Issuance of Stock Units							$ 1,135,000
Stock Units Description							Each Unit consisted of one common share of the Company, and a warrant to purchase one common share of the Company at an exercise price of $1.40 per share exercisable for 4 years.
Warrants Exercisable Period							4 years
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares				$ 0.80			$ 0.80
Payments of Stock Issuance Costs							$ 151,975
Class of Warrant or Right, Outstanding | shares				141,875			141,875
Sixth Closing [Member]
Stock Units Issued During Period | shares							2,035,000
Proceeds From Issuance of Stock Units							$ 1,628,000
Stock Units Description							Each Unit consisted of one common share of the Company, and a warrant to purchase one common share of the Company at an exercise price of $1.40 per share exercisable for 4 years.
Warrants Exercisable Period							4 years
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares				$ 0.80			$ 0.80
Payments of Stock Issuance Costs							$ 211,656
Class of Warrant or Right, Outstanding | shares				203,500			203,500
Fourth Closing [Member]
Stock Units Issued During Period | shares							3,115,000
Proceeds From Issuance of Stock Units							$ 2,492,000
Stock Units Description							Each Unit consisted of one common share of the Company, and a warrant to purchase one common share of the Company at an exercise price of $1.40 per share exercisable for 4 years.
Warrants Exercisable Period							4 years
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares				$ 0.80			$ 0.80
Payments of Stock Issuance Costs							$ 338,960
Class of Warrant or Right, Outstanding | shares				311,500			311,500
[1]	In June 2014, the Company issued 416,667 common shares for the exercise of stock options. The Company received cash of $228,875 ($250,000 CAD). The value of the options, $106,185, was transferred from contributed surplus to share capital on exercise.
[2]	In May, 2012, 200,000 common shares valued at $117,192 were issued for settlement of accounts payable relating to services performed in the prior year, which is included in general and administrative expenses for the year ended March 31, 2013.
[3]	The opening balance consists of 7,750,000 common shares issued to its two founders for a consideration of $2, 1,000,000 commons shares issued to two directors and 250,000 common shares to a consultant for a total of 1,250,000 common shares for consideration of $3.
[4]	In August, 2012, 125,000 common shares each issued to the two founders on March 24, 2011, for a total of 250,000 common shares were cancelled.
[5]	In May, 2012, the Company issued through a private placement, 291,667 common shares at a price of $0.59 (0.60 CAD) per share for aggregate gross proceeds of $170,815.
[6]	In June, 2012, the Company issued through a private placement, 895,834 common shares at a price of $0.58 (0.60 CAD) per share for aggregate gross proceeds of $519,420.
[7]	In September, 2012, the Company issued through a private placement, 437,500 common shares at a price of $0.59 (0.60 CAD) per share for aggregate gross proceeds of $256,016.
[8]	In December, 2012, the Company issued through a private placement, 383,333 common shares at a price of $0.61 (0.60 CAD) per share for aggregate gross proceeds of $232,546.
[9]	In March 2013, the Company issued through a private placement, 516,666 common shares at a price of $0.60 (0.60 CAD) per share for aggregate gross proceeds of $308,183. $58,846 of the proceeds were not received as at March 31, 2013 and accordingly are presented as subscriptions receivable on the balance sheet.
[10]	In June, 2013, the Company issued through a private placement, 166,667 common shares at a price of $0.58 ($0.60 CAD) per share for aggregate gross proceeds of $96,320.
[11]	In April, 2014, the Company completed a private placement issuing 3,182,978 common shares at a price of $0.82 ($0.90 CAD) per share for gross proceeds of $2,616,062 ($2,864,680 CAD). A former director of the Company assisted in securing a significant portion of this financing. As a result the Company issued 247,778 common shares as a finder’s fee to this director. The Company also incurred $11,609 in share issue costs related to the transaction.

STOCK OPTIONS (Details)

STOCK OPTIONS (Details) - Employee Stock Option [Member]	6 Months Ended	9 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life		7 years
Risk free rate		1.59%
Dividend yield		0.00%
Forfeiture rate		0.00%
Expected volatility		114.00%
February 17, 2015 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life	5 years
Risk free rate	1.59%
Dividend yield	0.00%
Forfeiture rate	0.00%
Expected volatility	114.00%
July 1, 2014 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life	4 years 4 months 6 days
Risk free rate	1.59%
Dividend yield	0.00%
Forfeiture rate	0.00%
Expected volatility	114.00%
June 20, 2014 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life	6 years 3 months 25 days
Risk free rate	1.59%
Dividend yield	0.00%
Forfeiture rate	0.00%
Expected volatility	114.00%
April 11, 2014 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life	4 years 1 month 20 days
Risk free rate	1.59%
Dividend yield	0.00%
Forfeiture rate	0.00%
Expected volatility	114.00%

STOCK OPTIONS (Details 1)

STOCK OPTIONS (Details 1) - Employee Stock Option [Member] - $ / shares	6 Months Ended	9 Months Ended	12 Months Ended
	Jun. 30, 2015	Dec. 31, 2014	Dec. 31, 2014	Mar. 31, 2014	Mar. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number Options, Outstanding, Beginning Balance (in shares)	1,198,000	416,667	1,310,665		0
Number Options, Exercised (in shares)		(416,667)	(1,310,665)
Number of Options, Granted (in shares)	314,560	1,238,000	3,894,252	416,667
Number of Options, Cancelled (in shares)	(157,281)	(40,000)	(125,824)
Number of Options, Cancelled as a result of Merger (in shares)	(3,768,428)
Number of Options, Re-issued as part of Acquisition Transaction (in shares)	3,768,428
Number of Options, Outstanding, Ending Balance (in shares)	3,925,707	1,198,000	1,198,000	416,667
Weighted Average Exercise Price, Outstanding, Beginning Balance (in dollars per share)	$ 0.74	$ 0.52	$ 0.19		$ 0
Weighted Average Exercise Price, Exercised (in dollars per share)		0.52	0.19
Weighted Average Exercise Price, Cancelled (in dollars per share)	0.23	0.52	0.17
Weighted Average Exercise Price, Granted (in dollars per share)	0.23	0.73	0.22	$ 0.52
Weighted-Average Exercise Price, Cancelled as a result of Merger (in dollars per share)	0.22
Weighted Average Exercise Price, Re-issued as part of Acquisition Transaction (in dollars per share)	0.22
Weighted Average Exercise Price, Outstanding, Ending Balance (in dollars per share)	$ 0.22	$ 0.74	$ 0.74	$ 0.52
Weighted Average Remaining Contractual Life, Outstanding		6 years 8 months 19 days		2 months 12 days	0 years
Weighted Average Remaining Contractual Life, Granted		7 years		0 years
Weighted Average Remaining Contractual Life, Exercised		0 years
Weighted Average Remaining Contractual Life, Cancelled		0 years

STOCK OPTIONS (Details 2)

STOCK OPTIONS (Details 2) - Employee Stock Option [Member] - $ / shares	6 Months Ended
	Jun. 30, 2015	Dec. 31, 2014	Mar. 31, 2014	Dec. 31, 2013	Mar. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 0.22	$ 0.74	$ 0.52	$ 0.19	$ 0
Number of Options	3,925,707	1,198,000	416,667	1,310,665	0
Number of Exercisable Options	3,555,580
Stock Option One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 0.165
Number of Options	531,606
Expiry Date	Apr. 1, 2021
Number of Exercisable Options	354,404
Stock Option Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 0.23
Number of Options	159,377
Expiry Date	Jun. 20, 2021
Number of Exercisable Options	123,727
Stock Option Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 0.23
Number of Options	2,972,592
Expiry Date	Jul. 1, 2021
Number of Exercisable Options	2,972,592
Stock Option Four [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 0.23
Number of Options	262,132
Expiry Date	Feb. 17, 2022
Number of Exercisable Options	104,857

STOCK OPTIONS (Details Textual)

STOCK OPTIONS (Details Textual)	3 Months Ended			6 Months Ended		9 Months Ended			12 Months Ended
	Jun. 30, 2015USD ($)shares	Mar. 31, 2015USD ($)$ / shares	Jun. 30, 2014USD ($)	Jun. 30, 2015USD ($)shares	Jun. 30, 2014USD ($)	Dec. 31, 2014USD ($)$ / sharesshares	Dec. 31, 2014CAD / shares	Dec. 31, 2013USD ($)	Mar. 31, 2014USD ($)$ / sharesshares	Mar. 31, 2014CAD / shares	Mar. 31, 2013USD ($)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense				$ 1,669,195	$ 90,286	$ 112,573		$ 0	$ 0		$ 117,192
Percentage Of Option Granted						8.00%
Stock Issued During Period, Value, Share-based Compensation, Gross				$ 1,669,195
Minimum Offering Amount						$ 6,000,000
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Outstanding Options | shares	10,800,000			10,800,000
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period | shares						125,824
Employee Stock Option One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | shares									416,667
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | (per share)									$ 0.52	CAD 0.60
Stock Issued During Period, Value, Share-based Compensation, Gross									$ 106,185
Employee Stock Option Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | shares						209,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | CAD / shares							CAD 0.60
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price | $ / shares						$ 0.52
Stock Issued During Period, Value, Share-based Compensation, Gross						$ 153,348
Stock Issued During Period, Shares, Share-based Compensation, Forfeited | shares						40,000
Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures						$ 112,573
Employee Stock Option Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price | $ / shares						$ 0.77
Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures						$ 719,835
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross Addition | shares						945,000
April issuance [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number | shares	531,606			531,606
Share Based Compensation Arrangement By Share Based Payment Award Options Remeasured Fair value				$ 230,930
Allocated Share-based Compensation Expense	$ 19,165		$ 14,194	$ 93,025	67,616
June issuance [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | shares				264,230
Share Based Compensation Arrangement By Share Based Payment Award Options Remeasured Fair value				$ 118,957
Allocated Share-based Compensation Expense	9,225		$ 5,554	$ 45,909	$ 22,670
June issuance [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period | shares				104,853
Employees and Consultant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period | shares				52,428
Employees and Consultant [Member] | April issuance [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | shares						657,430
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares						$ 0.165
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period | shares						657,430
Employees and Consultant [Member] | June issuance [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | shares						264,230
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares						$ 0.23
Management [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | shares						2,972,592
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares						$ 0.23
Share Based Compensation Arrangement By Share Based Payment Award Options Issued Weighted Average Remaining Contractual Term1						7 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value		$ 1,259,487
Consultant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | shares				314,560		84,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | (per share)		$ 0.23					CAD 0.90
Allocated Share-based Compensation Expense	$ 9,681			$ 60,451
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value		$ 136,613
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price | $ / shares						$ 0.77
Stock Issued During Period, Value, Share-based Compensation, Gross						$ 61,142

WARRANTS (Details)

WARRANTS (Details)	6 Months Ended
	Jun. 30, 2015$ / sharesshares
Number of Warrants, Outstanding and exercisable, December 31, 2014 and 2013	0
Number of Warrants, Issued	18,049,075
Number of Warrants, Outstanding and exercisable, June 30, 2015	18,049,075
Weighted-Average Exercise Price, Outstanding and exercisable, December 31, 2014 and 2013 | $ / shares	$ 0
Weighted-Average Exercise Price, Issued | $ / shares	1.35
Weighted-Average Exercise Price, Outstanding and exercisable, June 30, 2015 | $ / shares	$ 1.35

WARRANTS (Details 1)

WARRANTS (Details 1)	6 Months Ended
	Jun. 30, 2015$ / sharesshares
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Outstanding	18,049,075
Warrant One [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 1.40
Class of Warrant or Right, Outstanding	7,735,750
Class Of Warrant Or Right Expiry Date	Feb. 26, 2019
Warrant Two [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 0.80
Class of Warrant or Right, Outstanding	773,575
Class Of Warrant Or Right Expiry Date	Feb. 26, 2019
Warrant Three [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 1.40
Class of Warrant or Right, Outstanding	1,212,500
Class Of Warrant Or Right Expiry Date	Mar. 27, 2019
Warrant Four [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 0.80
Class of Warrant or Right, Outstanding	121,250
Class Of Warrant Or Right Expiry Date	Mar. 27, 2019
Warrant Five [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 1.40
Class of Warrant or Right, Outstanding	891,250
Class Of Warrant Or Right Expiry Date	Mar. 31, 2019
Warrant Six [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 0.80
Class of Warrant or Right, Outstanding	89,125
Class Of Warrant Or Right Expiry Date	Mar. 31, 2019
Warrant Seven [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 1.40
Class of Warrant or Right, Outstanding	3,115,000
Class Of Warrant Or Right Expiry Date	Apr. 21, 2019
Warrant Eight [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 0.80
Class of Warrant or Right, Outstanding	311,500
Class Of Warrant Or Right Expiry Date	Apr. 21, 2019
Warrant Nine [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 1.40
Class of Warrant or Right, Outstanding	1,418,750
Class Of Warrant Or Right Expiry Date	May 27, 2019
Warrant Ten [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 0.80
Class of Warrant or Right, Outstanding	141,875
Class Of Warrant Or Right Expiry Date	May 27, 2019
Warrant Eleven [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 1.40
Class of Warrant or Right, Outstanding	2,035,000
Class Of Warrant Or Right Expiry Date	Jun. 30, 2019
Warrant Twelve [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 0.80
Class of Warrant or Right, Outstanding	203,500
Class Of Warrant Or Right Expiry Date	Jun. 30, 2019

WARRANTS (Details Textual)

WARRANTS (Details Textual) - Pope And Co [Member]	9 Months Ended
	Dec. 31, 2014USD ($)$ / sharesshares	Dec. 31, 2014CAD
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 0.23
Warrants Expiration Period	2 years	2 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	349,522
Debt Instrument, Periodic Payment, Interest	$ 12,138	CAD 13,417

INCOME TAXES (Details)

INCOME TAXES (Details) - USD ($)	9 Months Ended	12 Months Ended
	Dec. 31, 2014	Mar. 31, 2014	Mar. 31, 2013
Components of net loss before income taxes consists of the following:
U.S.	$ 0	$ 0	$ 0
Canada	(2,464,747)	(1,451,769)	(937,059)
Net loss before recovery of income taxes	$ (2,464,747)	$ (1,451,769)	$ (937,059)
Statutory rate	26.50%	26.50%	26.50%
Expected income tax recovery	$ (653,158)	$ (384,719)	$ (248,321)
Other basis adjustment	(29,109)	(6,966)	(8,576)
Non-deductible expenses	193,305	148,936	(38,493)
Change in valuation allowance	488,962	242,749	295,390
Recovery of income taxes	$ 0	$ 0	$ 0

INCOME TAXES (Details 1)

INCOME TAXES (Details 1) - USD ($)	Dec. 31, 2014	Mar. 31, 2014	Mar. 31, 2013
Deferred Tax Assets And Liabilities [Line Items]
Deferred tax assets Current	$ 0	$ 403	$ 0
Valuation allowance	0	(403)	0
Deferred Tax Assets, Net of Valuation Allowance, Current	0	0	0
Long-term Unrealized tax credits	0	19,591	19,721
Property and equipment	36,940	23,985	0
Share issue costs	7,137	6,461	7,228
SR&ED pool	162,350	0	0
Other	18,621	0	0
Net operating losses	812,522	529,889	310,228
Valuation allowance	(1,037,570)	(579,926)	(337,177)
Deferred Tax Liabilities, Net	$ 0	$ 0	$ 0

RISK MANAGEMENT (Details Textua

RISK MANAGEMENT (Details Textual)	6 Months Ended		9 Months Ended		12 Months Ended
	Jun. 30, 2015USD ($)	Jun. 30, 2014USD ($)	Dec. 31, 2014USD ($)	Dec. 31, 2013USD ($)	Mar. 31, 2014USD ($)	Mar. 31, 2013USD ($)	Jun. 30, 2015CAD	Dec. 31, 2014CAD
Concentration Risk [Line Items]
Cash, FDIC Insured Amount | CAD							CAD 100,000	CAD 100,000
Stock Issued During Period, Value, New Issues		$ 2,616,062	$ 2,616,062		$ 96,320	$ 1,486,980
Proceeds from Stock Options Exercised	$ 0	$ 228,875	228,875	$ 0	$ 0	$ 0
Drywave Technologies Inc [Member]
Concentration Risk [Line Items]
Stock Issued During Period, Value, New Issues			$ 10,363,000

SUBSEQUENT EVENT (Details Textu

SUBSEQUENT EVENT (Details Textual)

1 Months Ended

3 Months Ended

6 Months Ended

9 Months Ended

12 Months Ended

Apr. 21, 2015USD ($)$ / sharesshares

Mar. 31, 2015USD ($)$ / sharesshares

Mar. 27, 2015USD ($)$ / sharesshares

Feb. 26, 2015USD ($)$ / shares$ / Unitshares

Feb. 25, 2015USD ($)shares

Feb. 25, 2015CADshares

Feb. 17, 2015USD ($)$ / sharesshares

Jan. 21, 2015USD ($)

Mar. 31, 2015USD ($)$ / sharesshares

Jun. 30, 2015USD ($)shares

Dec. 31, 2014USD ($)shares

Dec. 31, 2014CAD / shares

Mar. 31, 2013USD ($)

Aug. 14, 2015USD ($)shares

Subsequent Event [Line Items]

Loans and Leases Receivable, Related Parties | $

$ 150,000

Debt Instrument, Interest Rate, Stated Percentage

6.00%

Long-term Debt, Maturities, Repayment Terms

repayable in 10 months

Stock Issued During Period, Value, Issued for Services | $

$ 117,192

Class of Warrant or Right, Outstanding

18,049,075

Minimum Offering Amount | $

$ 6,000,000

April issuance [Member]

Subsequent Event [Line Items]

Share Based Compensation Arrangement By Share Based Payment Award Options Remeasured Fair value | $

$ 230,930

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number

531,606

June issuance [Member]

Subsequent Event [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

264,230

Share Based Compensation Arrangement By Share Based Payment Award Options Remeasured Fair value | $

$ 118,957

Director and Employees and Consultant [Member]

Subsequent Event [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

314,560

84,000

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | (per share)

$ 0.23

CAD 0.90

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value | $

$ 136,613

Subsequent Event [Member]

Subsequent Event [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

5.00%

Proceeds from Issuance of Debt | $

$ 500,000

Exchangeable Shares Issued

50,000,000

Percentage of Outstanding Common Shares

100.00%

Payments For Services | $

$ 135,000

Common Stock, Shares Subscribed but Unissued

102,500

Subsequent Event [Member] | April issuance [Member]

Subsequent Event [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value | $

$ 230,930

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number

531,606

Subsequent Event [Member] | June issuance [Member]

Subsequent Event [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value | $

$ 118,957

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number

264,230

Subsequent Event [Member] | Director and Employees and Consultant [Member]

Subsequent Event [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

314,560

100,000

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares

$ 0.23

$ 0.77

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value | $

$ 136,613

Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period

7 years

Subsequent Event [Member] | Term Loan [Member]

Subsequent Event [Line Items]

Loans and Leases Receivable, Related Parties | $

$ 150,000

Debt Instrument, Interest Rate, Stated Percentage

5.00%

Long-term Debt, Maturities, Repayment Terms

18 months

Subsequent Event [Member] | Exchangable Shares [Member]

Subsequent Event [Line Items]

Stock Issued During Period, Value, Issued for Services

$ 241,185

CAD 250,000

Stock Issued During Period, Shares, Issued for Services

262,904

262,904

Stock Transferred To Lenders

100,000

100,000

Stock Reimbursed To Officers

83,574

83,574

First Closing [Member] | Subsequent Event [Member]

Subsequent Event [Line Items]

Payments of Stock Issuance Costs | $

848,822

Proceeds From Issuance of Stock Units | $

$ 6,188,600

Stock Units Issued During Period, Purchase Price Per Unit | $ / Unit

0.80

Stock Units Description

Each Unit consists of one common share of BLC, and a warrant to purchase one common share of BLC at an exercise price of $1.40 per share exercisable for 4 years.

Business Acquisition, Percentage of Voting Interests Acquired

100.00%

Stock Units Issued During Period

7,735,750

First Closing [Member] | Subsequent Event [Member] | Broker warrants [Member]

Subsequent Event [Line Items]

Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares

$ 0.80

Warrant Exercisable Period

4 years

Class of Warrant or Right, Outstanding

773,575

Second Closing [Member] | Subsequent Event [Member]

Subsequent Event [Line Items]

Payments of Stock Issuance Costs | $

$ 141,100

Proceeds From Issuance of Stock Units | $

$ 970,000

Stock Units Description

Each Unit consisted of one common share of BLC, and a warrant to purchase one common share of BLC at an exercise price of $1.40 per share exercisable for 4 years.

Stock Units Issued During Period

1,212,500

Second Closing [Member] | Subsequent Event [Member] | Broker warrants [Member]

Subsequent Event [Line Items]

Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares

$ 0.80

Warrant Exercisable Period

4 years

Class of Warrant or Right, Outstanding

121,250

Third Closing [Member] | Subsequent Event [Member]

Subsequent Event [Line Items]

Payments of Stock Issuance Costs | $

$ 97,098

Proceeds From Issuance of Stock Units | $

$ 713,000

Stock Units Description

Each Unit consisted of one common share of BLC, and a warrant to purchase one common share of BLC at an exercise price of $1.40 per share exercisable for 4 years

Stock Units Issued During Period

891,250

Third Closing [Member] | Subsequent Event [Member] | Broker warrants [Member]

Subsequent Event [Line Items]

Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares

$ 0.80

$ 0.80

Warrant Exercisable Period

4 years

Class of Warrant or Right, Outstanding

89,125

89,125

Fourth Closing [Member]

Subsequent Event [Line Items]

Subsequent Event, Date

Apr. 21, 2015

Fourth Closing [Member] | Subsequent Event [Member]

Subsequent Event [Line Items]

Payments of Stock Issuance Costs | $

$ 338,960

Proceeds From Issuance of Stock Units | $

$ 2,492,000

Stock Units Description

Each Unit consisted of one common share of BLC, and a warrant to purchase one common share of BLC at an exercise price of $1.40 per share exercisable for 4 years

Stock Units Issued During Period

3,115,000

Fourth Closing [Member] | Subsequent Event [Member] | Broker warrants [Member]

Subsequent Event [Line Items]

Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares

$ 0.80

Warrant Exercisable Period

4 years

Class of Warrant or Right, Outstanding

311,500

Drywave Stockholders [Member] | First Closing [Member] | Subsequent Event [Member]

Subsequent Event [Line Items]

Stock Issued During Period, Shares, Acquisitions

6,000,000

Investor [Member] | First Closing [Member] | Subsequent Event [Member]

Subsequent Event [Line Items]

Stock Issued During Period, Shares, Acquisitions

7,735,750

Management [Member] | Subsequent Event [Member]

Subsequent Event [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

945,000

Options Vesting Period

90 days

Management [Member] | Subsequent Event [Member] | Amended [Member]

Subsequent Event [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

2,972,592

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares

$ 0.23

Share Based Compensation Arrangement By Share Based Payment Award Options Remeasured Fair value | $

$ 1,259,487

Bionik Laboratories Corp [Member] | Subsequent Event [Member] | Amended [Member] | April issuance [Member]

Subsequent Event [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

531,606

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares

$ 0.165

Bionik Laboratories Corp [Member] | Subsequent Event [Member] | Amended [Member] | June issuance [Member]

Subsequent Event [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

264,230

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares

$ 0.23

Uncategorized Items - bnkl-2015

Label	Element	Value
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs	us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	$ 11,609
Stock Issued During Period, Value, Conversion of Convertible Securities	us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	239,746
Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature	us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	27,677
Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition	us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	90,286
Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition	us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	22,287
Accumulated Other Comprehensive Income (Loss) [Member]
Net Income (Loss) Attributable to Parent	us-gaap_NetIncomeLoss	0
Net Income (Loss) Attributable to Parent	us-gaap_NetIncomeLoss	0
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent	us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	(3,098)
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent	us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	(2,455)
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs	us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	0
Stock Issued During Period, Value, Conversion of Convertible Securities	us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	0
Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature	us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	0
Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition	us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	0
Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition	us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	0
Stock Issued During Period, Value, Stock Options Exercised	us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised	0
Stock Issued During Period, Value, New Issues	us-gaap_StockIssuedDuringPeriodValueNewIssues	0
Additional Paid-in Capital [Member]
Net Income (Loss) Attributable to Parent	us-gaap_NetIncomeLoss	0
Net Income (Loss) Attributable to Parent	us-gaap_NetIncomeLoss	0
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent	us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	0
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent	us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	0
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs	us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	11,609
Stock Issued During Period, Value, Conversion of Convertible Securities	us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	238,734
Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature	us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	27,677
Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition	us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	90,286
Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition	us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	22,287
Stock Issued During Period, Value, Stock Options Exercised	us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised	227,564
Stock Issued During Period, Value, New Issues	us-gaap_StockIssuedDuringPeriodValueNewIssues	2,605,270
Common Stock [Member]
Net Income (Loss) Attributable to Parent	us-gaap_NetIncomeLoss	0
Net Income (Loss) Attributable to Parent	us-gaap_NetIncomeLoss	0
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent	us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	0
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent	us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	0
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs	us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	0
Stock Issued During Period, Value, Conversion of Convertible Securities	us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	1,012
Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature	us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	0
Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition	us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	0
Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition	us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	$ 0
Stock Issued During Period, Shares, Conversion of Convertible Securities	us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities	1,012,142
Preferred Stock [Member]
Net Income (Loss) Attributable to Parent	us-gaap_NetIncomeLoss	$ 0
Net Income (Loss) Attributable to Parent	us-gaap_NetIncomeLoss	0
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent	us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	0
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent	us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	0
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs	us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	0
Stock Issued During Period, Value, Conversion of Convertible Securities	us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	0
Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature	us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	0
Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition	us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	0
Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition	us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised	0
Stock Issued During Period, Shares, Conversion of Convertible Securities	us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities	0
Stock Issued During Period, Value, Stock Options Exercised	us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised	$ 0
Stock Issued During Period, Value, New Issues	us-gaap_StockIssuedDuringPeriodValueNewIssues	$ 0
Stock Issued During Period, Shares, New Issues	us-gaap_StockIssuedDuringPeriodSharesNewIssues	0
Retained Earnings [Member]
Net Income (Loss) Attributable to Parent	us-gaap_NetIncomeLoss	$ (787,099)
Net Income (Loss) Attributable to Parent	us-gaap_NetIncomeLoss	(1,760,129)
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent	us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	0
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent	us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	0
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs	us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	0
Stock Issued During Period, Value, Conversion of Convertible Securities	us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	0
Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature	us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	0
Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition	us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	0
Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition	us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	0
Stock Issued During Period, Value, Stock Options Exercised	us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised	0
Stock Issued During Period, Value, New Issues	us-gaap_StockIssuedDuringPeriodValueNewIssues	$ 0